fifth
intern
symposium
respiratori
viral
infect
conven
macra
group
new
york
ny
casa
de
campo
dominican
republ
decemb
symposium
provid
annual
forum
virologist
vaccinologist
clinician
pharmacologist
public
health
specialist
discuss
recent
advanc
respiratori
viru
research
interdisciplinari
fashion
summari
four
previou
meet
publish
antivir
research
ison
et
al
kaiser
et
al
munoz
et
al
schmidt
et
al
spectrum
discuss
rang
basic
virolog
pathogenesi
epidemiolog
immunolog
manag
strategi
particular
attent
vaccin
antivir
econom
issu
ror
lack
proof
read
mechan
turn
result
product
quasispeci
infect
individu
consequ
error
incred
genet
variabl
result
continu
antigen
drift
intermitt
antigen
shift
shift
result
introduct
new
strain
viru
often
result
pandem
see
tabl
interpandem
influenza
respons
death
per
year
addit
signific
morbid
loss
work
thompson
et
al
import
pandem
past
centuri
spanish
influenza
pandem
viru
infect
american
result
death
us
alon
death
rate
among
young
adult
age
year
time
higher
previou
year
depress
life
expect
american
year
pace
sever
pandem
best
document
histori
new
zealand
octob
sever
member
board
ss
niagara
becam
ill
influenza
sinc
boat
carri
prime
minist
massey
minist
health
fail
enforc
quarantin
boat
result
influenza
infect
much
citi
auckland
first
week
novemb
dub
citi
dead
result
breakdown
civil
servic
novemb
two
full
death
train
per
day
carri
dead
citi
like
us
mortal
rate
highest
among
peopl
age
year
interestingli
maori
higher
death
rate
european
find
suggest
prior
exposur
influenza
may
minim
mortal
jeffrey
taubenberg
sequenc
ha
na
ns
np
gene
spanish
influenza
viru
found
close
relat
swine
unfortun
molecular
basi
high
pathogen
viru
still
unknown
likewis
unclear
viru
hemagglutinin
neuraminidas
gene
deriv
avian
influenza
viru
directli
infect
man
infect
pig
pig
serv
intermedi
host
studi
recent
virus
demonstr
aquat
bird
natur
reservoir
influenza
virus
speci
wild
aquat
bird
influenza
viru
replic
predomin
intestin
tract
transmiss
via
fecalor
rout
often
water
limit
number
hostspecif
lineag
influenza
virus
bird
geograph
separ
eurasian
american
lineag
influenza
virus
natur
avian
reservoir
evolutionari
stasi
rapid
evolut
occur
transmiss
new
host
felt
swine
signific
intermedi
host
suscept
influenza
subtyp
receptor
avian
mammalian
influenza
virus
acquisit
avian
influenza
gene
swine
influenza
virus
document
isol
europ
canada
china
although
latter
two
instanc
transitori
unit
state
virus
becam
problem
pig
infect
associ
respiratori
sign
high
fever
f
high
morbid
high
risk
abort
respons
virus
highli
transmiss
result
variabl
mortal
interestingli
analysi
three
porcin
virus
reveal
viru
undergon
tripl
reassort
acquir
human
ha
na
gene
porcin
np
ns
gene
avian
pa
gene
grow
evid
swine
influenza
virus
acquir
avian
polymeras
gene
well
although
pig
appear
import
reservoir
mix
pot
potenti
human
influenza
virus
chicken
virus
recent
emerg
asia
suggest
chicken
may
also
import
intermediari
reassort
viru
contain
ha
gene
virus
began
circul
chicken
viru
transmit
human
result
six
death
patient
becam
infect
high
fever
nausea
vomit
diarrhea
pneumonia
addit
alter
hepat
renal
function
fortun
humantohuman
transmiss
outbreak
halt
massiv
slaughter
poultri
region
addit
studi
local
chicken
market
demonstr
viru
infect
chicken
result
death
chicken
coinfect
virus
protect
ill
effici
shed
viru
still
appear
problem
reemerg
differ
viru
fortun
outbreak
human
infect
prevent
massiv
slaughter
chicken
unfortun
multipl
differ
lineag
virus
gooseguangdong
ha
still
present
local
chicken
editori
note
februari
infect
avian
influenza
viru
result
two
death
hong
kong
famili
visit
southern
china
current
influenza
season
avian
influenza
caus
diseas
death
throughout
asia
upon
investig
outbreak
chicken
human
becam
clear
quail
might
play
signific
role
interspeci
transmiss
influenza
virus
appear
quail
acquir
infect
fecal
sourc
replic
viru
respiratori
tract
evid
tracheal
shed
viru
outbreak
chicken
associ
reintroduct
quail
market
address
concern
quail
intermedi
transmiss
influenza
quail
ban
poultri
market
hong
kong
addit
duck
gees
recogn
past
reservoir
influenza
virus
import
separ
poultri
kill
sold
chill
instead
previou
practic
sell
live
final
market
empti
clean
monthli
hope
reduc
transmiss
influenza
among
poultri
sinc
viru
caus
sever
diseas
human
alreadi
potenti
pandem
threat
sever
research
look
virul
factor
clinic
experi
document
viru
kill
chicken
infect
unless
coinfect
virus
likewis
viru
neurovirul
mice
ferret
human
mortal
high
postmortem
examin
two
individu
found
high
cytokin
level
sever
studi
subsequ
document
protein
antagonist
antivir
activ
sever
cytokin
seo
et
al
genet
comparison
gene
virus
human
avian
swine
equin
virus
identifi
singl
mutat
virul
virus
use
revers
genet
found
infect
due
virus
mutat
result
greater
viral
shed
symptom
pig
lack
inhibit
replic
typic
induc
cytokin
vitro
furthermor
invitro
infect
human
primari
macrophag
viru
upregul
express
mrna
encod
rant
caus
increas
elabor
proinflammatori
cytokin
understand
current
previou
pandem
virus
expand
techniqu
learn
viru
pathogenesi
one
major
advanc
multiplasmid
revers
genet
system
influenza
system
allow
scientist
make
influenza
virus
order
rapidli
prepar
high
growth
reassort
vaccin
rapidli
prepar
subtypespecif
vaccin
pandem
prepared
better
understand
molecular
basi
virul
host
rang
viru
unfortun
power
techniqu
bring
sever
challeng
sinc
easi
make
reassort
virus
could
possibl
creat
virus
sever
pathogen
gene
virus
highli
resist
antivir
result
highli
transmiss
lethal
agent
could
use
agent
bioterror
regard
danger
construct
need
contain
within
level
facil
limit
number
center
studi
prepar
futur
current
risk
bioterror
pandem
influenza
essenti
surveil
use
global
human
anim
network
yet
develop
biosensor
expand
addit
vaccin
product
need
studi
sinc
current
take
month
prepar
new
vaccin
may
mild
warn
wave
infect
next
pandem
lastli
antivir
need
stockpil
new
antivir
agent
need
develop
human
metapneumoviru
hmpv
discov
describ
group
erasmu
univers
van
den
hoogen
et
al
van
den
hoogen
et
al
sinc
serolog
studi
document
infect
patient
throughout
world
includ
dutch
antil
barbado
slovakia
finland
netherland
sudan
somalia
india
vietnam
chan
et
al
falsey
et
al
freymouth
et
al
howe
jartti
et
al
nissen
et
al
pelleti
et
al
b
peret
et
al
stockton
et
al
children
first
acquir
infect
first
year
life
infect
document
infant
first
year
life
although
infect
document
children
infect
occur
patient
age
preliminari
data
suggest
hmpv
may
respons
approxim
viral
respiratori
tract
ill
rti
children
rti
adult
among
primat
rhesu
monkey
chimp
frequent
antibodi
hmpv
less
frequent
found
orangutan
gibbon
experiment
challeng
studi
done
cynomolgu
macaqu
guinea
pig
ferret
chicken
turkey
bird
fail
becom
infect
macaqu
develop
diseas
evid
histopatholog
chang
tissu
nose
bronchiol
repeat
infect
macaqu
result
shorter
durat
shed
subsequ
infect
serum
iga
antibodi
fail
detect
second
infect
secondari
infect
result
low
level
hmpv
antibodi
product
fail
induc
heterologu
antibodi
relat
avian
pneumoviru
apv
sequenc
n
p
f
sh
g
l
gene
indic
hmpv
close
relat
apv
van
den
hoogen
et
al
hydrophil
plot
f
reveal
two
hydrophob
region
similar
apv
rsv
g
protein
five
glycosyl
site
appear
two
genet
serotyp
cluster
hmpv
two
subclust
cluster
guy
boivin
laval
univers
canada
new
paramyxoviru
human
metapneumoviru
hmpv
recent
isol
dutch
children
respiratori
symptom
van
den
hoogen
et
al
howev
preval
clinic
present
sever
hmpv
infect
children
well
studi
multiplex
realtim
pcr
assay
use
detect
viral
pathogen
influenza
influenza
b
respiratori
syncyti
viru
rsv
hmpv
nasopharyng
aspir
hospit
children
year
acut
respiratori
tract
infect
arti
winter
spring
season
children
hospit
surgeri
without
respiratori
symptom
use
control
hmpv
detect
children
hospit
arti
compar
rsv
influenza
viru
detect
symptomat
patient
one
pathogen
includ
one
case
coinfect
hmpv
influenza
none
virus
detect
control
rsv
influenza
infect
occur
januaryfebruari
wherea
peak
hmpv
activ
seen
marchapril
overal
clinic
present
complic
associ
hmpv
infect
similar
caus
rsv
fever
versu
cough
versu
rhinorrhea
versu
wheez
versu
hmpv
rsv
respect
hmpv
associ
bronchiol
otiti
media
pneumonia
infect
children
hmpv
children
sick
enough
requir
admiss
intens
care
unit
mean
hospit
stay
day
children
infect
hmpv
rsv
influenza
although
sever
hmpv
infect
less
frequent
caus
hrsv
clinic
present
two
viral
pathogen
virtual
ident
dr
boivin
also
discuss
outbreak
investig
appear
nosocomi
outbreak
hmpv
nurs
home
give
inform
impact
new
viru
summari
hmpv
true
respiratori
pathogen
associ
signific
morbid
children
dual
respiratori
viral
infect
two
wors
one
robert
couch
baylor
colleg
medicin
houston
tx
multipl
respiratori
virus
detect
sometim
patient
respiratori
tract
ill
variou
studi
frequenc
dual
infect
rang
virusinfect
patient
studi
document
dual
infect
patient
frequenc
dual
infect
appear
higher
children
adult
type
diagnost
techniqu
util
greatli
impact
detect
virus
studi
adult
patient
mani
underli
lung
diseas
develop
respiratori
infect
dual
infect
document
patient
cell
cultur
alon
use
serolog
ad
cultur
rtpcr
ad
previou
two
techniqu
drew
et
al
frequent
isol
virus
patient
dual
infect
includ
picornavirus
n
influenza
coronavirus
rsv
adenovirus
parainfluenza
virus
influenza
b
three
common
combin
picornavirus
influenza
n
cornoaviru
adenoviru
drew
et
al
question
answer
period
sebastian
johnston
report
studi
respiratori
viral
ill
children
histori
wheez
patient
dual
infect
tripl
infect
exacerb
impact
dual
infect
diseas
cours
also
studi
volunt
coinocul
hrv
anoth
picornaviru
simultan
infect
infect
picornaviru
approxim
week
initi
hrv
infect
sequenti
infect
infect
two
virus
simultan
differ
viru
shed
diseas
sever
wherea
sequenti
infect
reduc
viru
shed
diseas
sever
comparison
volunt
infect
fleet
et
al
exact
mechan
reduct
viral
shed
symptom
sever
known
transient
immun
previou
infect
may
contribut
effect
children
present
lower
respiratori
ill
rsv
alon
combin
anoth
respiratori
viru
studi
find
differ
sever
durat
ill
two
studi
document
increas
sever
symptom
one
document
increas
durat
ill
andreoletti
et
al
cate
et
al
meissner
et
al
papadopoulo
et
al
portnoy
et
al
ray
et
al
smith
et
al
subbarao
et
al
tristram
et
al
tsai
et
al
preliminari
data
dr
johnston
studi
also
document
clear
increas
sever
asthma
exacerb
increas
number
infect
virus
although
well
control
studi
time
infect
type
virus
like
impact
durat
sever
ill
avail
inform
insuffici
firm
conclus
ill
consequ
dual
respiratori
viral
infect
futur
studi
address
relationship
ill
sever
etiolog
time
cours
quantit
virolog
dual
infect
respiratori
pathogen
first
year
life
birth
cohort
studi
use
pcr
sebastian
johnston
imperi
colleg
london
uk
numer
studi
document
associ
asthma
exacerb
respiratori
viral
ill
rvi
approxim
children
adult
present
asthma
exacerb
detect
viru
time
exacerb
sever
recent
studi
expand
understand
epidemiolog
rvi
relationship
asthma
exacerb
unpublish
studi
present
group
perform
viral
cultur
pcr
rsv
human
rhinovirus
hrv
nasal
aspir
children
age
year
hospit
upper
respiratori
tract
ill
urti
wheez
ninetysix
percent
children
year
age
posit
one
two
virus
rsv
rhinoviru
dual
infect
children
year
older
detect
viru
rhinoviru
result
confirm
high
frequenc
rvi
patient
agerel
chang
pathogen
distribut
observ
earlier
studi
predomin
rhinoviru
infect
age
year
second
studi
collect
nasal
aspir
within
h
admiss
among
infant
admit
bronchiol
seventythre
percent
patient
viru
detect
pcr
rsv
hrv
adenoviru
influenza
parainfluenza
coronaviru
dual
infect
document
patient
patient
rsv
infect
tend
younger
month
versu
month
p
higher
birth
weight
hrv
infect
patient
hrv
infect
alon
hospit
earlier
ill
episod
day
versu
day
p
higher
likelihood
clinic
sever
score
admiss
percentil
p
control
age
gender
birth
weight
presenc
fever
day
diseas
admiss
patient
dual
infect
hospit
later
ill
rsv
hrv
alon
day
versu
day
p
versu
day
p
consist
interpret
dual
infect
sequenti
event
papadopoulo
et
al
anoth
recent
unpublish
epidemiolog
studi
western
australian
childhood
asthma
studi
conduct
dr
peter
sli
patrick
holt
merci
kusel
enrol
newli
born
infant
least
one
parent
physiciandiagnos
atop
diseas
acut
respiratori
ill
record
first
year
life
home
visit
studi
nurs
arrang
within
h
onset
ill
assess
symptom
collect
nasal
aspir
two
control
visit
done
child
asymptomat
first
month
life
subsequ
month
children
respect
develop
upper
respiratori
tract
ill
uri
nonwheezi
lower
respiratori
tract
ill
lri
develop
children
first
subsequ
month
respect
wheezi
lri
develop
respect
among
first
sampl
juli
februari
ari
control
control
posit
picornaviru
rsv
compar
ari
sampl
picornaviru
rsv
dual
infect
among
uri
picornavirus
rsv
dual
infect
nonwheez
lri
associ
picornaviru
detect
rsv
dual
infect
wheez
lri
associ
picornaviru
case
rsv
dual
infect
ratio
uri
lri
picornaviru
rsv
although
rsv
perhap
like
associ
sever
lower
respiratori
tract
ill
data
indic
rhinovirus
major
respiratori
pathogen
first
year
life
caus
three
time
mani
lri
first
year
life
rsv
nonhospit
infant
specif
picornaviru
caus
ill
remain
identifi
pcr
test
coronavirus
influenza
b
parainfluenza
virus
adenovirus
hmpv
mycoplasma
pneumonia
chlamydia
pneumonia
progress
molecular
epidemiolog
adenoviru
type
respiratori
infect
adriana
e
kajon
lovelac
respiratori
research
institut
albuquerqu
nm
adenovirus
constitut
import
group
human
pathogen
capac
caus
wide
rang
ill
man
adenovirus
respons
case
pediatr
acut
respiratori
infect
ari
requir
hospit
nosocomi
outbreak
adenoviru
respiratori
infect
frequent
report
adenoviru
virion
consist
nonenvelop
icosohedr
capsid
enclos
doublestrand
dna
genom
approxim
bp
human
adenoviru
famili
current
compris
serotyp
classifi
six
speci
formerli
subgenera
af
base
genom
characterist
tropism
associ
diseas
biolog
properti
respiratori
diseas
mainli
caus
adenoviru
serotyp
classifi
within
subspeci
speci
c
speci
e
among
preval
serotyp
associ
human
respiratori
diseas
adenoviru
type
frequent
caus
sever
clinic
present
children
young
adult
caus
epidem
acut
febril
respiratori
ill
among
militari
recruit
ryan
et
al
extrapulmonari
manifest
rare
fatal
residu
lung
damag
observ
associ
infect
becroft
steenjohnsen
et
al
affect
patient
surviv
sever
diseas
may
chronic
sequela
form
bronchiectasi
bronchiol
obliteran
hyperluc
lung
murtagh
kajon
restrict
enzym
analysi
strain
shown
exist
consider
intraserotyp
genet
variabl
last
two
decad
report
molecular
epidemiolog
studi
infect
shown
certain
genom
type
predomin
area
long
period
time
replac
new
genom
type
molecular
base
substitut
one
genom
type
anoth
call
genom
type
shift
select
forc
drive
adenoviru
evolut
natur
unknown
moreov
impact
genet
variabl
adenoviru
virul
poorli
understood
shift
occur
europ
australia
wadel
et
al
shift
occur
china
li
et
al
shift
took
place
south
america
argentina
chile
uruguay
kajon
wadel
still
preval
genom
type
isol
europ
north
america
still
recov
nasopharyng
secret
children
hospit
ari
south
america
observ
suggest
adapt
advantag
array
gene
preced
preval
genom
type
region
interestingli
recent
detect
unit
state
japan
associ
respiratori
ill
brazil
associ
acut
conjunct
find
suggest
recent
introduct
dissemin
viru
previous
geograph
restrict
area
circul
origin
report
circul
china
later
japan
israel
identifi
recent
outbreak
ari
unit
state
affect
children
militari
traine
gerber
et
al
major
neutral
epitop
differ
genom
type
hypervari
region
hexon
exhibit
high
degre
conserv
amino
acid
level
except
li
wadel
find
suggest
genom
type
shift
strongli
determin
select
antigen
variant
initi
studi
genet
variabl
region
viral
genom
encod
immunomodulatori
function
horwitz
identifi
sequenc
differ
region
among
variou
genom
type
occurr
intermedi
variant
hexon
gene
fiber
gene
also
detect
kajon
wadel
howev
implic
genet
variat
human
diseas
still
unclear
remain
elus
genom
type
character
phenotyp
correl
genotyp
phenotyp
establish
spanish
flu
pandem
result
signific
morbid
mortal
part
high
rate
viral
pneumonia
lower
respiratori
tract
complic
recent
certain
gene
viru
sequenc
help
determin
respons
virul
revers
genet
use
creat
virus
influenza
awsn
background
contain
gene
strain
contemporari
strain
recent
experi
conduct
laboratori
three
virus
creat
wildtyp
wsn
viru
wsn
viru
ha
na
gene
wsn
viru
ha
na
gene
mice
ld
hana
viru
compar
wild
type
hana
virus
lung
titer
infect
mice
higher
wildtyp
hana
virus
hana
viru
degre
lung
inflamm
sever
evid
signific
hemorrhag
mice
infect
hana
viru
least
hana
viru
viral
antigen
distribut
differ
lung
three
virus
day
wsn
wildtyp
viru
predomin
bronchiol
hana
viru
evid
diffus
involv
pulmonari
parenchyma
hana
viru
minim
stain
lower
airway
lastli
anoth
recombin
viru
construct
background
wildtyp
viru
nonleth
mice
viru
ha
na
gene
uniformli
lethal
find
indic
ha
na
viru
link
part
virul
mammalian
host
protect
viru
could
achiev
antivir
antibodi
current
avail
antiinfluenza
agent
excel
activ
strain
influenza
respons
pandem
tumpey
et
al
antibodi
test
residu
blood
sampl
patient
high
level
antibodi
direct
ha
present
blood
patient
born
gener
concept
origin
antigen
sin
human
expos
vaccin
influenza
produc
higher
antibodi
first
viru
expos
subsequ
virus
may
explain
find
turn
could
partli
explain
older
patient
may
rel
protect
rel
younger
individu
pandem
anoth
question
recent
answer
although
signific
still
investig
viru
packag
analysi
gene
influenza
document
segment
influenza
conserv
noncod
region
end
sever
studi
conduct
determin
segment
incorpor
random
select
first
virus
segment
creat
assess
effici
virion
product
cell
cultur
viru
replic
greatest
segment
present
least
present
next
revers
genet
use
creat
two
virus
one
na
gene
replac
gene
green
floresc
protein
gfp
conserv
noncod
flank
base
pair
ncfbp
ncfbpgfpncfbp
anoth
gfp
flank
ncfbp
na
gene
ncfbpnagfpnancfbp
gfp
segment
infect
cell
made
gfp
compar
nagfp
segment
suggest
although
ncfbp
requir
code
region
case
na
requir
incorpor
new
virion
addit
studi
document
virion
incorpor
signal
vi
frequent
contain
uau
code
region
uniqu
segment
gene
ha
np
requir
vi
end
na
ns
gene
requir
vi
end
lastli
packag
segment
within
virion
assess
electron
microscopi
demonstr
like
interact
base
pair
segment
result
segment
align
one
anoth
fix
way
fujii
et
al
interact
requir
greater
studi
potenti
target
drug
vaccin
futur
abil
recov
infecti
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
serotyp
clone
cdna
techniqu
call
revers
genet
offer
new
approach
develop
live
attenu
vaccin
main
challeng
creat
potenti
live
vaccin
develop
viru
highli
stabil
attenu
maintain
satisfactori
level
immunogen
revers
genet
use
achiev
goal
creat
array
potenti
mutat
fine
tune
level
attenu
increas
immunogen
viru
decreas
reactogen
rsv
piv
modular
genom
organ
piv
rsv
short
cisact
rna
signal
make
virus
highli
amen
genet
manipul
vaccin
candid
rsv
strain
subgroup
previous
develop
convent
biolog
mean
involv
passag
suboptim
temperatur
cold
passag
cp
follow
chemic
mutagenesi
identif
temperatur
sensit
ts
deriv
sever
strain
evalu
clinic
one
call
shown
infecti
immunogen
protect
second
vaccin
dose
infant
target
age
rsv
vaccin
howev
retain
abil
caus
mild
nasal
congest
thu
would
requir
attenu
prove
unfeas
convent
method
virus
sequenc
mutat
identifi
phenotyp
confer
confirm
incorpor
wild
type
recombin
viru
provid
list
known
attenu
mutat
list
expand
find
number
rsv
gene
includ
sh
could
delet
yield
deriv
prove
attenu
vivo
new
knowledg
appli
revers
genet
creat
two
new
virus
sh
sh
second
show
promis
earli
clinic
trial
appear
free
residu
virul
virus
develop
contain
highlyattenu
gene
delet
contain
variou
combin
gene
delet
point
mutat
revers
genet
also
use
increas
gene
stabil
prevent
revers
incorpor
multipl
point
mutat
design
amino
acid
substitut
involv
least
two
nucleotid
chang
compar
assign
yield
wild
type
wild
typelik
phenotyp
employ
gene
delet
investig
suggest
move
g
f
gene
proxim
locat
genom
result
increas
effici
g
f
express
enhanc
immunogen
likewis
delet
orf
put
regulatori
factor
result
shift
rna
synthesi
rna
replic
transcript
concomit
increas
antigen
express
might
also
possibl
reduc
reactogen
rsv
vaccin
use
strategi
develop
immunobiolog
studi
one
exampl
would
ablat
secret
form
g
implic
preferenti
sensit
lymphocyt
revers
genet
also
use
creat
rsv
subgroup
b
vaccin
candid
replac
g
f
protect
antigen
gene
rsv
subgroup
vaccin
candid
subgroup
b
g
f
counterpart
revers
genet
also
appli
develop
vaccin
candid
promis
vaccin
candid
previous
develop
convent
approach
cold
passag
nucleotid
sequenc
identifi
potenti
attenu
mutat
character
revers
genet
major
attenu
mutat
found
involv
three
ts
mutat
l
three
nont
mutat
c
f
revers
genet
use
develop
addit
mean
attenu
includ
silenc
c
v
open
read
frame
well
novel
strategi
import
mutat
correspond
gene
heterolog
virus
use
amino
acid
sequenc
align
identifi
correspond
residu
bovin
b
repres
complet
differ
vaccin
strategi
one
base
find
antigen
relat
natur
attenu
primat
jennerian
strategi
analog
use
cowpox
viru
vaccin
small
pox
strategi
improv
use
revers
genet
construct
version
f
hn
major
antigen
determin
replac
counterpart
thu
provid
fulli
homolog
immun
chimer
viru
retain
attenu
phenotyp
repres
promis
vaccin
candid
basi
host
rang
restrict
investig
replac
individu
gene
couterpart
show
gene
made
individu
contribut
attenu
phenotyp
suggest
vaccin
base
attenu
backbon
stabl
also
indic
introduct
individu
gene
addit
strategi
attenu
one
pursu
version
contain
n
gene
revers
genet
also
appli
live
vaccin
candid
present
avail
attenu
anim
viru
counterpart
potenti
jennerian
vaccin
strategi
import
mutat
particular
rsv
particularli
use
result
develop
number
attenu
mutat
serv
basi
live
vaccin
final
revers
genet
use
creat
attenu
chimer
viru
vector
protect
multipl
paramyxovirus
one
multival
candid
use
abovement
chimer
viru
vector
rsv
f
g
gene
viru
thu
combin
two
vaccin
one
importantli
backbon
replic
cell
cultur
effici
express
higher
level
protein
rsv
avoid
physic
instabl
characterist
rsv
chimer
vaccin
exhibit
satisfactori
level
attenu
immunogen
rsv
evalu
rhesu
monkey
develop
clinic
evalu
avail
piv
vector
express
rsv
antigen
offer
novel
approach
immun
altern
provid
effici
method
boost
initi
vaccin
made
live
rsv
viru
anticip
method
result
develop
live
vaccin
rsv
prefer
would
given
first
week
life
caus
diseas
somewhat
later
first
year
life
vaccin
could
begin
month
age
kevin
l
russel
navel
health
research
center
san
diego
ca
infect
caus
influenza
adenoviru
common
among
militari
personnel
also
make
less
prepar
battl
current
threat
biowarfar
addit
avail
antiinfluenza
drug
prevent
treatment
make
rapid
identif
pathogen
essenti
medic
personnel
militari
battlefield
situat
ambient
storag
transport
specimen
would
desir
depart
defens
center
deploy
health
research
naval
health
research
center
arm
forc
institut
patholog
fort
jackson
armi
recruit
train
center
collabor
assess
perform
pcr
assay
influenza
adenoviru
sampl
store
ambient
temperatur
comparison
viral
cultur
use
frozen
fresh
sampl
armi
recruit
fort
jackson
sc
present
oral
temperatur
f
cough
sore
throat
studi
period
decemb
march
two
nasal
swab
collect
one
inocul
viral
transport
media
frozen
c
later
viral
cultur
store
ethanol
ambient
temperatur
sampl
collect
symptomat
recruit
viral
cultur
posit
patient
influenza
b
adenoviru
type
dual
infect
observ
cultur
techniqu
pcr
detect
influenza
patient
adenoviru
patient
patient
pcr
posit
adenoviru
influenza
result
confirm
greater
sensit
nucleic
acid
detect
method
compar
cultur
circumst
sensit
specif
cultur
consid
pcr
gold
standard
respect
adenoviru
respect
influenza
direct
comparison
pcr
posit
sampl
frozen
immedi
versu
specimen
store
ambient
temperatur
although
studi
plan
season
sinc
room
temperatur
storag
techniqu
easier
accomplish
locat
sinc
pcr
techniqu
wide
avail
militari
techniqu
use
studi
expand
abil
provid
respiratori
pathogen
surveil
sever
subsequ
studi
current
way
standard
methodolog
equip
militari
provid
inform
yield
molecular
techniqu
time
collect
specimen
month
collect
unfortun
world
appear
prepar
pandem
influenza
thirtyon
countri
plan
four
formal
plan
slovak
republ
norway
new
zealand
canada
plan
base
phase
outlin
global
agenda
influenza
http
wwwwhointinfluenza
outlin
four
major
area
associ
prioriti
activ
guidelin
vaccin
develop
widespread
concern
vaccin
product
lag
behind
need
hope
increas
awar
import
pandem
plan
develop
nation
pandem
plan
likewis
hope
increas
util
vaccin
antivir
develop
strategi
acquir
util
new
vaccin
antivir
lastli
advoc
addit
research
pandem
virus
effort
heard
recent
round
meet
discuss
bioterror
set
asid
time
discuss
influenza
pandem
plan
although
progress
made
pandem
may
occur
time
greater
step
need
taken
minim
potenti
impact
unit
state
depart
health
human
servic
establish
interag
pandem
influenza
work
group
input
center
diseas
control
food
drug
administr
nation
institut
health
depart
defens
offic
gener
council
offic
plan
evalu
offic
emerg
prepared
nation
vaccin
advisori
committe
goal
work
group
develop
plan
limit
burden
diseas
minim
social
disrupt
reduc
econom
loss
influenza
pandem
goal
met
three
object
improv
surveil
respons
infrastructur
sever
action
propos
strengthen
nation
global
capabl
virolog
diseas
surveil
view
increas
likelihood
earli
detect
virus
pandem
potenti
first
global
influenza
surveil
network
site
countri
collabor
center
atlanta
london
melbourn
tokyo
expand
improv
increas
collabor
cdc
form
laboratori
epidemiolog
train
taken
place
past
decad
anim
influenza
surveil
also
enhanc
collabor
nih
partner
cdc
work
state
expand
sentinel
physician
network
current
includ
physician
state
district
columbia
work
ongo
establish
system
monitor
hospit
case
influenza
facilit
transfer
technolog
via
train
reagent
distribut
us
depart
defens
surveil
site
also
contribut
global
influenza
surveil
interag
pandem
influenza
work
group
also
focus
improv
nation
readi
respond
pandem
cdc
develop
plan
guid
state
local
health
offici
http
wwwcdcgovodnvpo
pandemicfluhtm
help
develop
pandem
plan
guid
state
avail
internet
focu
plan
creat
decisionmak
protocol
respons
pandem
develop
flexibl
conting
plan
procur
distribut
vaccin
antivir
reduc
liabil
risk
priorit
group
receipt
vaccin
andor
antivir
improv
readi
also
focus
identif
specif
resourc
requir
respons
includ
addit
medic
personnel
medic
vaccin
webbas
program
fluaid
http
develop
help
state
estim
potenti
impact
influenza
third
perhap
largest
object
work
group
strengthen
influenzarel
public
health
practic
infrastructur
research
success
compon
object
promot
adult
immun
program
improv
vaccin
coverag
individu
increas
risk
complic
influenza
sever
group
develop
commun
network
protocol
dissemin
uptod
inform
healthcar
provid
public
research
influenza
biolog
epidemiolog
anim
surveil
vaccin
antivir
develop
continu
support
nih
grant
academ
research
grant
support
publicpriv
partnership
develop
cell
culturebas
vaccin
test
human
candid
pandem
vaccin
made
use
revers
genet
classic
reassort
techniqu
encourag
also
need
test
adjuv
vaccin
develop
new
antivir
agent
noteworthi
current
two
influenza
vaccin
manufactur
licens
distribut
vaccin
us
influenza
season
also
noteworthi
produc
vaccin
purchas
privat
take
nearli
full
year
time
select
strain
product
usabl
vaccin
result
essenti
encourag
new
vaccin
manufactur
new
approach
includ
revers
genet
prepar
seed
strain
addit
develop
implement
vaccin
polici
ensur
adequ
fair
procur
distribut
vaccin
influenza
pandem
polici
need
take
account
liabil
protect
equit
global
access
final
identifi
appropri
antivir
drug
stockpil
develop
plan
priorit
use
antivir
necessari
pandem
prepared
despit
progress
made
work
group
mani
obstacl
remain
prevent
effect
implement
pandem
prepared
plan
essenti
polici
maker
public
understand
potenti
threat
influenza
pose
mankind
firm
polit
financi
commit
made
minim
impact
pandem
best
defens
influenza
pandem
strengthen
capac
respond
season
epidem
influenza
improv
surveil
increas
vaccin
use
enhanc
vaccin
product
develop
effect
vaccin
deliveri
infrastructur
could
function
effect
emerg
polici
maker
take
advantag
integr
bioterror
plan
pandem
influenza
prepared
develop
flexibl
sciencebas
polici
combin
effort
better
prepar
next
pandem
influenza
despit
signific
progress
made
countri
pandem
influenza
plan
europ
still
infanc
major
obstacl
pandem
plan
europ
lack
central
plan
organ
depend
nation
govern
address
public
health
issu
first
pandem
plan
meet
european
union
member
includ
polici
maker
scientist
industri
brussel
belgium
novemb
sinc
eu
draft
pandem
plan
guidanc
draft
guidelin
prepar
cdc
produc
current
circul
discuss
addit
iv
taskforc
develop
two
import
subcommitte
polici
practic
commun
committe
scienc
product
regul
spr
committe
spr
committe
develop
goal
creat
highyield
seed
product
influenza
viru
librari
help
medimmun
cdc
european
fluplan
partner
enhanc
revers
genet
technolog
spr
also
work
enhanc
reagent
avail
speed
regulatori
clearanc
futur
vaccin
antivir
collect
clinic
data
safeti
necessari
antigen
concentr
appropri
adjuv
dose
schedul
immunogen
candid
vaccin
addit
hope
move
studi
forward
allow
proof
concept
novel
vaccin
technolog
one
studi
direct
look
amount
antigen
need
rel
product
capac
vaccin
use
sever
differ
scenario
current
trival
vaccin
requir
g
antigen
viru
product
capac
within
europ
million
dose
per
week
monoval
vaccin
use
combin
potent
adjuv
requir
antigen
could
potenti
reduc
g
increas
capac
million
dose
per
week
two
recent
meet
help
identifi
candid
vaccin
virus
collect
data
enhanc
vaccin
efficaci
use
adjuv
develop
protocol
fast
track
registr
vaccin
signific
issu
europ
countri
vaccin
product
capac
leav
nation
depend
other
suppli
vaccin
estim
million
dose
shortfal
vaccin
eu
pandem
likewis
yet
concert
effort
stockpil
antivir
agent
suppli
agent
limit
three
group
activ
work
pandem
influenza
issu
europ
current
european
scientif
work
group
influenza
meet
address
pandem
prepared
european
influenza
surveil
scheme
design
collect
exchang
inform
influenza
activ
throughout
europ
current
encompass
physician
laboratori
countri
pandem
plan
develop
european
influenza
surveil
scheme
particip
countri
although
implement
plan
part
limit
final
european
union
fund
fifth
framework
program
includ
fluplan
novaflu
program
hope
address
develop
novel
vaccin
vaccin
strategi
formul
australia
develop
framework
influenza
pandem
plan
begun
implement
recommend
influenza
pandem
plan
committe
ippc
charter
develop
conting
plan
make
recommend
infrastructur
strategi
requir
minim
mortal
morbid
social
disrupt
econom
loss
associ
influenza
pandem
work
committe
recommend
publish
comprehens
document
incorpor
appendix
conting
plan
health
care
institut
prepar
victorian
state
plan
http
wwwhealthgovaupubhlthstrategcommun
techinfluenzahtm
condens
actionori
version
plan
subsequ
adopt
communic
diseas
network
basi
action
major
recommend
mainten
ongo
pandem
plan
committe
impact
model
adopt
alert
improv
interpandem
use
vaccin
develop
antivir
stockpil
develop
commun
strategi
nation
pandem
action
committe
nipac
recent
form
follow
term
refer
interpandem
period
assist
govern
develop
nation
polici
vaccin
strategi
surveil
antivir
stockpil
establish
work
parti
progress
polici
issu
action
plan
collabor
state
territori
prepar
plan
revis
promot
action
plan
consider
chang
global
agenda
regularli
report
progress
depart
health
age
follow
declar
pandem
initi
nation
respons
monitor
pandem
facilit
commun
alert
govern
regard
urgent
issu
advis
action
reduc
public
health
risk
evalu
pandem
respons
similarli
australian
state
move
pandem
action
plan
howev
whilst
step
taken
pandem
plan
elev
within
bureaucraci
yet
signific
commit
fund
littl
region
involv
apart
represent
collabor
centr
australia
yet
contribut
greatli
global
pandem
prepared
health
econom
benefit
influenza
vaccin
firmli
establish
influenza
vaccin
use
increas
worldwid
especi
develop
countri
year
approxim
million
dose
vaccin
distribut
dose
use
countri
outsid
north
america
western
europ
australia
new
zealand
world
influenza
vaccin
produc
eight
develop
countri
locat
western
europ
north
america
australia
suscept
pandem
influenza
depend
whether
viru
reemerg
viru
similar
one
infect
peopl
past
exampl
influenza
entir
new
viru
like
avian
influenza
viru
appear
hong
kong
influenza
like
viru
peopl
age
year
approxim
world
popul
like
immunolog
prime
past
infect
requir
one
booster
dose
vaccin
viru
entir
new
one
prime
everyon
probabl
requir
two
dose
moreov
clinic
effect
costeffect
vaccin
older
adult
also
younger
adult
children
wide
appreci
health
offici
mani
countri
may
choos
vaccin
popul
thu
number
dose
vaccin
need
pandem
much
larger
number
current
use
year
interpandem
year
compani
sell
influenza
vaccin
contract
public
health
author
directli
distributor
institut
employ
physician
price
low
vaccin
gener
consid
commod
product
compani
health
author
alik
reason
compani
make
conserv
estim
much
vaccin
produc
year
demand
vaccin
increas
suddenli
pandem
threat
appear
vaccin
compani
probabl
lack
product
capac
respond
adequ
quickli
pandem
vaccin
probabl
monoval
rather
trival
theoret
possibl
number
dose
might
produc
could
increas
threefold
nonetheless
pandem
vaccin
still
like
short
suppli
countri
prudent
nation
health
offici
may
choos
lock
futur
suppli
pandem
vaccin
negoti
longterm
forward
contract
vaccin
compani
canadian
health
offici
negoti
contract
canada
sole
domest
produc
contract
written
countri
pandem
threat
appear
within
period
month
score
countri
tri
negoti
contract
pandem
vaccin
suppli
small
number
compani
negoti
chaotic
part
fruitless
moreov
like
compromis
nation
vaccin
product
countri
influenza
vaccin
compani
polit
leader
unit
state
swine
influenza
vaccin
product
canadian
health
offici
rememb
well
one
reason
sign
contract
domest
influenza
vaccin
produc
polit
leader
countri
without
vaccin
compani
option
new
approach
must
devis
guarante
adequ
suppli
pandem
vaccin
meet
level
demand
countri
new
approach
must
address
follow
six
major
issu
pandem
threat
appear
delay
prepar
seed
strain
vaccin
product
might
overcom
use
revers
genet
prepar
seed
strain
principl
revers
genet
could
use
prepar
highgrowth
variant
effici
product
may
essenti
pandem
viru
avian
origin
mani
virus
grow
poorli
embryon
egg
cultur
system
use
current
influenza
vaccin
product
long
issu
regard
worker
safeti
intellectu
properti
right
attach
revers
genet
sort
beforehand
promis
techniqu
could
key
factor
ensur
adequ
product
pandem
vaccin
whether
pandem
threat
due
reemerg
novel
eg
viru
determin
kind
vaccin
produc
also
whether
one
two
dose
requir
everi
effort
must
made
determin
minim
antigen
content
dose
accept
immunogen
studi
conduct
mani
year
ago
indic
whole
cell
vaccin
immunogen
split
viru
subunit
prepar
similar
antigen
content
moreov
recent
studi
shown
adjuv
vaccin
probabl
need
least
first
dose
studi
need
extend
larger
seri
clinic
trial
candid
pandemiclik
vaccin
trial
must
publicli
fund
design
determin
optim
characterist
pandem
vaccin
vaccin
schedul
current
regulatori
requir
delay
registr
pandem
vaccin
western
europ
immunogen
studi
must
undertaken
vaccin
compani
year
order
regist
product
trial
costli
time
consum
requir
north
america
australia
moreov
widespread
intern
trade
influenza
vaccin
interpandem
year
next
pandem
trade
like
much
extens
pandem
vaccin
deliv
quickli
countri
need
global
protocol
requir
allow
pandem
vaccin
produc
compani
regist
use
countri
world
need
protocol
global
registr
pandem
vaccin
consid
next
pandem
threat
appear
countri
better
prepar
next
pandem
increas
use
influenza
vaccin
interpandem
year
start
canadian
provinc
ontario
extend
recommend
influenza
vaccin
peopl
month
age
one
reason
institut
program
better
prepar
pandem
health
offici
help
prepar
next
pandem
expand
influenza
vaccin
recommend
extend
program
public
reimburs
vaccin
interpandem
year
tradit
market
approach
provid
interpandem
vaccin
abl
meet
global
demand
pandem
vaccin
although
mani
vaccin
compani
expand
product
facil
still
difficult
estim
futur
demand
interpandem
pandem
vaccin
unlik
situat
pediatr
vaccin
precis
estim
size
futur
target
popul
well
known
one
way
overcom
uncertainti
futur
demand
influenza
vaccin
would
obtain
countryspecif
data
number
dose
influenza
vaccin
distribut
year
vaccin
compani
rapidli
report
total
number
dose
distribut
per
popul
countri
b
obtain
roll
forecast
demand
interpandem
pandem
vaccin
health
offici
countri
avail
past
futur
inform
would
challeng
health
offici
make
comprehens
plan
vaccin
program
help
compani
make
realist
plan
vaccin
product
polit
leader
vaccineproduc
countri
probabl
prohibit
export
domest
produc
pandem
vaccin
countri
certain
nation
need
met
result
countri
vaccin
compani
includ
mani
current
use
larg
amount
vaccin
interpandem
year
may
find
difficult
imposs
obtain
suppli
pandem
vaccin
prevent
happen
intern
polit
agreement
must
negoti
beforehand
ensur
adequ
product
equit
distribut
pandem
vaccin
vaccineproduc
nonproduc
countri
european
commiss
begun
europ
someth
similar
need
done
entir
world
effect
plan
pandem
influenza
global
vaccin
suppli
requir
skill
expert
virolog
epidemiolog
vaccin
equal
import
howev
skill
expert
polit
econom
law
coordin
effort
intern
level
difficult
task
must
undertaken
question
health
benefit
success
certain
challeng
present
extraordinarili
compel
good
rapid
diagnost
test
realli
peter
wright
vanderbilt
univers
medic
center
nashvil
tn
ruth
karron
john
hopkin
univers
baltimor
md
rapid
diagnost
test
respiratori
viral
ill
becom
increasingli
import
tool
advent
effect
antivir
agent
maxim
effect
start
earli
cours
ill
need
isol
patient
could
pass
infect
ill
patient
need
differenti
viral
ill
respiratori
tract
pathogen
includ
bioterror
agent
howev
current
avail
rapid
test
mani
limit
area
improv
need
address
includ
abil
test
know
agent
improv
collect
method
improv
integr
diagnosi
use
medic
clinic
care
use
diagnost
epidemiolog
vaccin
develop
increas
sensit
adult
immunocompromis
patient
improv
eas
accuraci
test
rapid
test
current
avail
rsv
influenza
wide
basi
signific
limit
test
includ
sensit
specif
depend
qualiti
sampl
collect
time
ill
intens
epidem
popul
test
assay
develop
allow
sentinel
surveil
although
posit
predict
valu
limit
begin
end
epidem
see
addit
rapid
test
help
identifi
patient
may
benefit
antivir
agent
decreas
use
antibiot
shorten
durat
hospit
avail
rapid
test
rsv
respect
characterist
review
elsewher
recent
caliendo
rapid
test
influenza
use
three
major
method
fluoresc
antibodi
fa
antigen
detect
techniqu
neuraminidas
detect
polymeras
chain
reaction
pcr
fa
test
rapid
turnaroundtim
tat
min
h
unfortun
requir
intact
cell
collect
fluid
expert
reader
fluoresc
microscop
abl
distinguish
influenza
b
sensit
specif
hornsleth
jankowski
storch
cost
us
screen
us
identifi
influenza
pcr
take
slightli
longer
tat
h
requir
expert
technician
special
expens
equip
unfortun
pcr
avail
center
clinic
assay
rapid
test
includ
bectondickinson
influenza
influenza
ab
enzym
immunoassay
eia
zstat
flu
endogen
viral
encod
assay
evea
fluoia
optic
immunoassay
oia
quickvu
influenza
later
flow
immunoassay
lfia
binax
flu
flu
b
immunochromatograph
membran
ict
assay
zstat
flu
quickvu
influenza
binax
flua
flub
current
cliawaiv
allow
inclin
test
featur
differ
assay
summar
recent
nicholson
et
al
unfortun
report
sensit
specif
variou
test
directli
compar
sinc
differ
gold
standard
sourc
popul
sampl
type
fresh
versu
frozen
nasal
versu
throat
oper
ie
research
laboratori
versu
clinic
laboratori
versu
physician
offic
use
evalu
test
use
particular
rapid
diagnost
test
influenza
determin
accord
level
identif
need
influenza
b
versu
influenza
b
price
clia
statu
specimen
type
staff
familiar
method
turnaroundtim
rel
sensit
specif
test
addit
predict
valu
depend
preval
diseas
exampl
sensit
specif
test
preval
influenza
posit
predict
valu
ppv
test
would
preval
ppv
would
rapid
test
best
use
individu
strong
pretest
probabl
influenza
influenza
season
clinic
import
exampl
hospit
patient
neg
rapid
test
result
confirm
cultur
respons
respiratori
viral
infect
mediat
interact
within
mucos
surfac
contain
epitheli
cell
alveolar
cell
dendrit
cell
macrophag
innat
immun
system
includ
natur
killer
cell
neutrophil
macrophag
adapt
immun
system
includ
b
cell
interact
occur
result
mediat
includ
preform
one
like
collectin
includ
surfact
protein
spa
spd
induc
mediat
collectin
cytokin
chemokin
granul
product
antibodi
sever
signal
pathway
use
modul
immun
respons
follow
infect
viral
infect
epithelium
interact
pattern
recognit
receptor
tolllik
receptor
creation
viruscollectin
complex
result
upregul
mediat
gene
predomin
cytokin
chemokin
viruscollectin
complex
also
enhanc
phagocytosi
viral
protein
bind
b
cell
receptor
result
increas
antibodi
mediat
product
viral
protein
bind
cell
receptor
result
activ
cell
increas
mediat
product
chemokin
cytokin
elabor
respons
infect
interact
receptor
result
chemotaxi
regul
gene
express
ultim
result
immun
respons
evalu
role
specif
mediat
receptor
signal
pathway
respons
respiratori
viru
infect
anim
experi
particularli
mice
frequent
use
three
type
mice
use
experi
transgen
mice
gene
encod
molecul
interest
overexpress
express
abnorm
locat
tissu
knockout
mice
specif
gene
gene
segment
delet
knockin
mice
mutat
form
gene
replac
wildtyp
version
exampl
collectindefici
mice
use
influenza
rsv
infect
model
spd
defici
mice
increas
sensit
rsv
influenza
infect
increas
inflamm
increas
lung
viru
titer
delay
viru
clearanc
spa
defici
mice
similar
phenotyp
studi
suggest
collectin
regul
innat
adapt
immun
respons
sinc
rsvf
protein
bind
tolllik
receptor
defici
mice
use
immunopathogenesi
studi
role
toll
receptor
rsv
infect
defici
mice
impair
clearanc
rsv
lung
defici
effect
influenza
clearanc
defici
mice
also
diminish
pulmonari
synthesi
rsv
infect
defect
recruit
activ
nk
cell
therefor
consid
major
mediat
rsv
clearanc
hayn
et
al
interferon
play
key
role
control
mani
viral
infect
typic
interferon
receptor
gene
knock
instead
interferon
gene
numer
gene
code
type
interferon
surviv
lung
viru
titer
clearanc
influenza
receptor
knockout
mice
differ
observ
normal
mice
price
et
al
interferon
may
limit
influenza
viru
dissemin
strain
replic
outsid
respiratori
tract
process
difficult
model
mice
sever
knockout
mice
use
better
understand
impact
adapt
immun
respons
influenza
viru
infect
bcell
function
test
use
mt
j
h
c
k
knockout
mhc
class
ii
knockout
use
understand
role
knockout
use
understand
role
cell
studi
knockout
deficit
compon
adapt
immun
system
result
enhanc
suscept
infect
delay
viru
clearanc
increas
pulmonari
inflamm
injuri
follow
influenza
infect
recoveri
infect
mediat
remain
adapt
immun
respons
conjunct
ongo
innat
immun
respons
experi
mice
suggest
resist
repeat
infect
heterosubtyp
immun
mediat
part
b
cell
role
secretori
antibodi
studi
use
iga
j
chain
polyig
receptor
knockout
studi
demonstr
secretori
iga
requir
recoveri
pulmonari
infect
secretori
iga
may
enhanc
clearanc
homotyp
heterosubtyp
viru
upper
respiratori
tract
follow
infect
final
role
cell
lytic
machineri
studi
use
perforin
fa
fa
ligand
knockout
mice
perforin
defici
impact
influenza
clearanc
result
delay
clearanc
viru
increas
inflamm
rsv
infect
fa
ligand
defici
impact
influenza
clearanc
combin
defect
perforin
fa
ligand
result
delay
clearanc
influenza
cell
taken
togeth
understand
contribut
individu
compon
immun
system
clearanc
viru
surviv
host
follow
influenza
rsv
infect
advanc
use
genet
modifi
anim
innat
adapt
host
immun
respons
contribut
viru
clearanc
recoveri
experiment
influenza
rsv
infect
innat
adapt
host
respons
cooper
redund
immunolog
memori
respiratori
tract
may
accur
reflect
system
greater
understand
innat
adapt
immun
respons
may
possibl
develop
vaccin
improv
efficaci
abil
modul
pulmonari
injuri
rsv
highli
infecti
nearli
children
serolog
evid
infect
end
second
year
known
infect
infant
develop
sever
diseas
wherea
major
mild
symptom
respons
infect
host
produc
complex
mixtur
cytokin
inflammatori
mediat
antivir
also
potenti
patholog
properti
variou
clinic
experiment
observ
indic
certain
pattern
host
respons
associ
sever
diseas
extrem
difficult
prove
causal
determin
rather
correl
clinic
outcom
better
understand
associ
clinic
respons
infect
phenotyp
specif
gene
genet
associ
studi
need
done
genet
associ
studi
done
use
genom
approach
use
candid
gene
estim
genom
approach
would
requir
studi
least
marker
sever
thousand
subject
project
would
cost
mani
million
dollar
reason
candid
gene
approach
use
group
sever
candid
gene
identifi
may
play
role
immun
respons
rsv
includ
receptor
receptor
primari
object
current
genet
associ
studi
identifi
host
factor
contribut
develop
sever
lower
respiratori
tract
diseas
follow
infect
rsv
studi
address
problem
molecular
genet
approach
investig
whether
diseas
suscept
relat
common
polymorph
host
gene
thought
critic
protect
andor
pathogenesi
uk
studi
enrol
infant
less
year
old
sever
rsv
bronchiol
dna
sampl
patient
patient
parent
ethnic
match
cord
blood
control
collect
analyz
date
case
collect
includ
complet
famili
sampl
first
gene
analyz
potent
neutrophil
chemoattract
activ
previous
demonstr
promot
polymorph
may
influenc
level
gene
express
associ
sever
bronchiol
odd
ratio
bronchiol
chang
aa
chang
also
suggest
polymorph
predispos
subsequ
wheez
ill
bronchiol
followup
studi
children
admit
hospit
rsv
bronchiol
found
frequent
children
experienc
subsequ
wheez
frequenc
children
without
wheez
differ
control
bronchiol
versu
current
work
direct
fine
map
bronchiol
suscept
effect
preliminari
studi
suggest
also
link
ra
effector
gene
locat
downstream
gene
locu
also
investig
variant
major
receptor
rant
sever
polymorph
associ
level
cell
surfac
certain
polymorph
associ
progress
hiv
found
promot
snp
singl
nucleotid
polymorph
associ
sever
bronchiol
without
risk
factor
combin
studi
suggest
innat
immun
respons
airway
epitheli
cell
infect
rsv
appear
import
determin
diseas
sever
anoth
area
interest
rsv
pathogenesi
relat
chromosom
contain
sever
marker
associ
atopi
ige
level
wheez
ill
sever
cytokin
gene
map
region
includ
found
common
haplotyp
human
carri
associ
increas
risk
sever
rsv
bronchiol
korean
studi
children
month
old
rsv
lower
respiratori
tract
infect
blood
donor
differ
haplotyp
also
found
associ
sever
diseas
choi
et
al
result
suggest
may
function
variant
locu
identifi
differ
haplotyp
differ
popul
affect
diseas
sever
addit
preliminari
data
suggest
rare
haplotyp
found
human
also
affect
risk
bronchiol
exposur
rsv
conclus
data
genet
associ
studi
indic
innat
adapt
immun
respons
import
determin
sever
rsv
diseas
genet
associ
studi
shed
light
pathogenesi
sever
rsv
diseas
well
provid
inform
may
allow
target
therapi
infant
especi
high
risk
approach
could
extend
common
respiratori
viral
infect
due
influenza
rhinoviru
understand
differ
diseas
express
effici
rsv
infect
cell
involv
bind
cell
surfac
glycosaminoglycan
gag
heparin
sulfat
chondroitin
sulfat
gag
long
chain
repeat
disaccharid
typic
residu
length
present
surfac
proteoglycan
extracellular
matrix
attach
sialic
acid
decor
cell
surfac
glycoprotein
glycolipid
although
gag
also
report
contribut
attach
contrast
usual
practic
employ
monolay
cultur
immort
cell
line
present
studi
investig
rsv
infect
primari
human
airway
epitheli
hae
cell
cell
grown
support
cultur
upon
establish
airliquid
interfac
differenti
multilay
pseudostratifi
polar
tissu
close
resembl
airway
epithelium
vivo
regard
morpholog
function
includ
mucu
product
ciliari
motion
cilia
limit
apic
surfac
cell
keratan
sulfat
frequent
present
ciliat
cell
detect
immunolog
wild
type
recombin
rsv
genet
engin
express
green
fluoresc
protein
rgrsv
ad
gene
infect
could
monitor
real
time
live
cell
rgrsv
could
infect
cell
appli
apic
surfac
basolater
surfac
furthermor
viru
appear
infect
ciliat
keratan
sulfateexpress
cell
mechan
damag
tissu
expos
underli
layer
cell
increas
rang
infect
indic
reflect
authent
tropism
rather
simpl
physic
exclus
next
viru
appli
cell
cultur
differ
stage
develop
infect
ineffici
earli
develop
tissu
day
establish
airliquid
interfac
effici
increas
increas
differenti
reach
plateau
day
correspond
appear
ciliat
cell
viru
also
shown
shed
apic
surfac
reason
steadi
level
infect
plaqu
form
unit
per
ml
wash
fluid
time
microscopi
demonstr
welldefin
spread
rsv
across
apic
face
consist
cilia
motion
ribavirin
palivizumab
inhibit
infect
cell
thirtysix
day
rgrsv
infect
intact
infect
cell
readili
detect
interestingli
cytopatholog
effect
minim
although
cell
note
becom
rounder
vertic
dimens
studi
show
rsv
infect
apic
surfac
keratan
sulfatecontain
ciliat
cell
rsv
infect
minim
cytopath
effect
absenc
syncytia
like
due
polar
express
f
protein
similar
model
creat
use
express
gfp
like
rsv
appear
infect
bud
spread
via
apic
surfac
also
appear
infect
ciliat
cell
appear
infect
keratin
sulfatecontain
cell
well
subset
lack
keratin
sulfat
unlik
rsv
abl
infect
undifferenti
cell
effici
differenti
cell
infect
appear
complet
depend
sialic
acid
apic
cell
surfac
lastli
like
rsv
caus
visibl
damag
tissu
caus
chang
cell
shape
associ
rsv
model
system
may
help
identifi
cellular
receptor
rsv
use
studi
epitheli
cell
respons
infect
staphylococcu
aureu
common
caus
nosocomi
infect
unit
state
nosocomi
aureu
outbreak
link
healthcar
worker
concern
rais
aureu
could
spread
air
increas
risk
aureu
airborn
transmiss
associ
increas
aureu
nose
male
sex
snort
sneez
antibiot
use
cutan
diseas
viral
infect
phenomenon
entitl
cloud
babi
origin
describ
eichenwald
newborn
infant
nasal
colon
aureu
airborn
dispers
aureu
associ
upper
respiratori
tract
viral
infect
uri
eichenwald
et
al
cloud
babi
capabl
caus
outbreak
hospit
home
concept
expand
includ
adult
outbreak
aureu
infect
occur
two
newborn
nurseri
associ
singl
nurs
outbreak
investig
note
likelihood
nurs
transmit
aureu
increas
fivefold
period
time
upper
respiratori
infect
belani
et
al
possibl
cloud
adult
exist
substanti
investig
anoth
pointsourc
outbreak
aureu
nosocomi
pneumonia
outbreak
tie
singl
physician
uri
outbreak
last
week
coincid
respiratori
symptom
physician
experiment
infect
rhinoviru
open
agar
plate
place
around
detect
airborn
dispers
follow
rhinoviru
infect
increas
airborn
dispers
aureu
increas
could
decreas
wear
mask
sherertz
et
al
investig
concept
cloud
adult
special
chamber
design
laminar
airflow
maintain
hepa
filter
use
purifi
air
airborn
dispers
aureu
found
greatest
street
cloth
worn
chamber
less
steril
garb
don
without
mask
least
steril
garb
mask
use
greatest
amount
aureu
cultur
volunt
infect
rhinoviru
approxim
twofold
mean
increas
airborn
dispers
aureu
follow
experiment
rhinoviru
infect
peak
airborn
dispers
high
greater
baselin
mask
blunt
effect
wear
barrier
garb
gown
glove
booti
cap
suggest
volunt
airborn
dispers
come
real
time
directli
nose
independ
predictor
detect
aureu
area
around
volunt
includ
wear
street
cloth
sneez
rhinoviru
infect
cough
sever
cold
relat
aureu
coloni
count
greatest
coloni
count
obtain
catarrh
phase
ill
recent
studi
shown
coagulaseneg
staphylococci
increas
airborn
dispers
rhinoviru
infect
suggest
cloud
phenomenon
may
occur
organ
find
may
quit
import
suggest
possibl
mechan
outbreak
meningococc
pneumococc
streptococc
group
infect
occur
commun
semiclos
popul
aftermath
outbreak
influenza
viral
uri
one
potenti
hypothesi
explain
pathogenesi
cloud
adult
infect
result
inflamm
turn
reduc
diamet
nasal
passag
increas
rate
airflow
associ
aerosol
particul
includ
bacteria
venturi
effect
test
hypothesi
volunt
allerg
rhiniti
medic
held
cultur
viru
place
test
chamber
stop
medic
increas
airborn
dispers
aureu
inflammatori
respons
nose
rhinoviru
may
central
mechan
airborn
dispers
imperi
colleg
london
uk
rsv
bronchiol
infanc
strongli
associ
later
develop
asthma
stein
et
al
rsv
also
implic
viru
induc
asthma
exacerb
protect
immun
reinfect
rsv
incomplet
short
durat
previous
infect
infant
adult
remain
suscept
reinfect
antigen
close
relat
virus
ident
viru
strain
recent
evid
suggest
virusinduc
asthma
exacerb
may
associ
defici
type
immun
papadopoulo
et
al
deficit
mrna
ratio
mrna
express
peripher
blood
mononuclear
cell
pbmc
observ
infant
develop
rsv
bronchiol
compar
infant
birth
cohort
normal
respons
rsv
infect
legg
et
al
type
induc
cytokin
produc
resid
airway
cell
respons
inflammatori
stimuli
infect
promot
longterm
surviv
nk
memori
cell
ii
type
function
product
cytotox
nk
nk
cell
memori
cell
play
import
role
antivir
immun
respons
biron
et
al
carson
et
al
kennedi
et
al
liu
et
al
zhang
et
al
hypothes
type
cytokin
rich
environ
occur
asthmat
airway
virusinduc
product
type
cytokin
downregul
test
hypothesi
studi
rsvinduc
product
respiratori
epitheli
cell
absenc
presenc
cell
human
lung
type
alveolar
carcinoma
cell
line
infect
rsv
strain
presenc
ngml
absenc
control
rsv
induc
product
cell
timeand
dosedepend
manner
experi
conduct
presenc
show
downregul
product
rsv
infect
decreas
product
lung
respiratori
viral
infect
asthmat
subject
may
possibl
pathway
defici
antivir
immun
respons
delay
viru
erad
virusinduc
exacerb
atop
asthma
studi
direct
includ
repeat
experi
cell
line
primari
bronchial
epitheli
cell
gene
express
studi
defin
mechan
rsvinduc
product
downregul
comparison
product
respiratori
viral
infect
normal
asthmat
subject
rsv
childhood
wheez
asthma
atopi
peter
openshaw
imperi
colleg
london
uk
asthma
definit
revers
airflow
obstruct
chang
fev
perf
bronchial
hyperrespons
irrit
exercis
chemic
allergen
cold
air
patient
wheez
cough
short
breath
evid
increas
inflamm
lung
wheez
classifi
four
type
predomin
distinct
age
transient
infant
wheez
like
relat
exposur
smoke
small
lung
earli
wheez
typic
viral
ill
classic
atop
asthma
tend
famili
chronic
obstruct
airway
diseas
typic
result
chronic
irrit
exposur
smoke
throughout
person
lifetim
children
follow
birth
age
never
wheez
transient
wheez
onset
wheez
year
age
persist
wheez
martinez
et
al
five
six
million
american
children
asthma
make
common
chronic
diseas
children
estim
hospit
per
year
death
per
year
estim
excess
expenditur
us
billion
per
year
worldwid
result
asthma
exacerb
result
signific
burden
mani
studi
asthma
relationship
respiratori
viral
diseas
particularli
rsv
one
studi
children
hospit
rsv
lower
respiratori
tract
ill
lri
first
year
life
compar
control
mild
rsv
upper
tract
ill
patient
lower
tract
ill
significantli
increas
risk
wheez
year
age
sigur
et
al
anoth
studi
compar
children
mild
rsv
lri
control
children
without
lri
first
year
life
patient
lri
statist
signific
increas
frequenc
wheez
compar
control
age
stein
et
al
total
nine
control
studi
year
followup
conduct
demonstr
increas
frequenc
lower
respiratori
tract
symptom
andor
airflow
obstruct
bronchiol
enrol
patient
studi
lower
respiratori
symptom
within
year
within
year
within
year
within
year
hall
et
al
henri
et
al
webb
et
al
investig
potenti
link
rsv
bronchiol
asthma
wenzel
colleagu
conduct
longterm
followup
studi
children
bronchopulmonari
dysplasia
pbd
treat
rsv
polyclon
immunoglobulin
rsvig
infanc
agematch
control
bpd
receiv
rsvig
unfortun
group
match
sex
male
children
treat
group
rsv
lri
versu
cat
exposur
howev
year
enrol
rsvig
treat
children
significantli
better
ratio
airway
conduct
addit
less
atopi
miss
school
cold
asthma
attack
hospit
use
asthma
medic
wenzel
et
al
result
rais
question
whether
normal
lung
becom
asthmat
viral
infect
weaken
lung
would
becom
asthmat
without
infect
also
increas
risk
wheez
viral
infect
address
question
collect
peripher
blood
mononuclear
cell
children
histori
rsv
bronchiol
without
histori
rsv
bronchiol
pbmc
thaw
stimul
number
antigen
elispot
prolifer
assay
perform
bronchiolit
patient
increas
respons
rsv
fel
antigen
test
antigen
der
p
bet
v
tetanu
toxoid
pha
media
pala
et
al
second
studi
took
mice
expos
intranas
ovalbumin
follow
intraven
ovalbumin
day
initi
exposur
mice
expos
intranas
ovalbumin
expos
rsv
influenza
anaphylact
reaction
intraven
ovalbumin
mice
expos
without
infect
minim
symptom
odonnel
openshaw
taken
togeth
result
suggest
mild
infect
result
low
level
product
bronchiol
result
increas
product
addit
pala
et
al
age
acquisit
rsv
infect
may
impact
futur
asthmat
sequela
case
rsv
bronchiol
occur
prior
month
age
time
birth
neonat
strong
immun
respons
wherea
respons
matur
exposur
environment
antigen
viral
gastrointestin
infect
promot
respons
respons
protect
atopi
immun
matur
hypothes
document
stimul
tonsil
extract
children
rsv
pha
vitro
stimul
result
increas
level
increas
age
mice
infect
rsv
day
week
age
reinfect
week
age
infect
older
mice
result
increas
viral
load
like
secondari
larger
lung
cell
infect
similar
rate
clearanc
viru
secondari
infect
caus
substanti
weight
loss
mice
primarili
infect
day
week
mice
initi
infect
week
mice
primarili
infect
day
week
increas
number
total
cell
cell
eosinophil
neutrophil
extract
lung
mice
infect
week
increas
product
decreas
product
compar
mice
infect
day
week
culley
et
al
data
suggest
natur
secondari
respons
determin
age
primari
infect
rsv
infect
earli
life
sensit
sever
respons
viral
challeng
later
life
tcell
prime
neonat
period
may
explain
associ
delay
rsv
infect
beyond
infanc
could
longterm
benefit
term
less
sever
diseas
decreas
atopi
lower
frequenc
asthma
potenti
mechan
delay
effect
includ
chronic
persist
latent
viral
infect
remodel
lung
infect
perman
epitheli
damag
immunolog
prime
toler
bystand
antigen
sensit
studi
need
done
investig
altern
sever
studi
suggest
infect
infanc
protect
asthma
allerg
diseas
lower
respiratori
tract
viral
ill
associ
wheez
later
life
gener
infect
induc
type
respons
allerg
disord
associ
type
respons
type
type
respons
mutual
counterregulatori
immun
respons
birth
skew
toward
type
microbi
exposur
requir
develop
type
respons
environment
exposur
earli
life
like
contribut
matur
immun
system
children
larg
famili
lower
birth
order
marker
increas
exposur
microb
reduc
risk
develop
hay
fever
eczema
allergen
sensit
likewis
hepat
like
marker
load
infecti
exposur
associ
decreas
risk
allergi
matricardi
et
al
respiratori
viru
infect
associ
increas
risk
wheez
ill
atop
sensit
rsv
strongest
associ
sigur
et
al
tucson
children
respiratori
infect
studi
shed
light
onto
infect
children
initi
follow
year
age
sampl
collect
virolog
studi
child
experienc
sign
symptom
lower
respiratori
tract
ill
children
follow
visit
year
age
evalu
wheez
increas
risk
later
wheez
lower
respiratori
tract
ill
develop
result
rsv
infect
howev
lower
respiratori
tract
ill
result
viru
type
also
significantli
associ
increas
risk
wheez
later
life
stein
et
al
anoth
studi
found
substanti
contribut
rhinovirus
sever
bronchiol
papadopoulo
et
al
potenti
explan
relationship
earli
virusrel
lower
respiratori
ill
includ
rsv
bronchiol
patient
lower
respiratori
illnessbronchiol
may
smaller
airway
defici
type
increas
type
immun
develop
increas
allergen
sensit
acut
infect
evalu
potenti
explan
legg
associ
collect
nasal
lavag
day
ill
peripher
blood
mononuclear
cell
day
ill
children
first
year
life
proven
rsv
infect
time
point
infant
bronchiol
higher
ratio
nasal
lavag
depress
level
mrna
ratio
mrna
express
blood
mononuclear
cell
compar
infant
uri
slower
clearanc
viru
pcr
viral
load
seen
patient
bronchiol
legg
et
al
result
author
conclud
rsv
bronchiol
associ
defici
type
immun
impair
viru
clearanc
mallia
johnston
day
care
attend
greater
two
sibl
increas
risk
wheez
earli
life
decreas
risk
later
life
ball
et
al
other
also
found
differ
risk
wheez
patient
uri
compar
lri
patient
two
episod
uri
year
age
reduc
risk
asthma
year
age
patient
lri
wheez
increas
risk
illi
et
al
conclus
appear
risk
allerg
diseas
later
life
reduc
high
overal
load
infecti
diseas
includ
respiratori
viral
infect
earli
life
exposur
respiratori
infect
earli
life
caus
increas
morbid
time
likewis
individu
infect
subject
risk
defici
type
immun
small
airway
result
infect
sever
like
involv
lower
respiratori
tract
strongli
associ
wheez
later
life
michael
boeckh
fred
hutchinson
cancer
research
center
seattl
wa
increasingli
respiratori
virus
recogn
signific
pathogen
transplant
recipi
seriou
ill
due
respiratori
virus
appear
common
hematopoiet
stem
cell
transplant
hsct
recipi
lung
transplant
recipi
frequent
isol
respiratori
virus
respiratori
syncyti
viru
parainfluenza
influenza
virus
rhinovirus
target
surveil
system
found
attack
rate
among
approxim
patient
receiv
hsct
fred
hutchinson
cancer
research
center
fhcrc
past
year
piv
rsv
influenza
respiratori
viru
infect
rvi
seattl
area
like
temper
area
occur
winter
month
novemb
may
seattl
retrospect
review
found
respiratori
viral
pneumonia
associ
increas
risk
death
hr
rsv
piv
influenza
likewis
patient
respiratori
viral
infect
increas
risk
invas
aspergillosi
hr
marr
et
al
find
suggest
clinic
effect
rvi
like
direct
lytic
effect
indirect
immunomodulatori
effect
recent
group
fhcrc
conduct
retrospect
studi
hsct
recipi
determin
incid
risk
factor
outcom
respiratori
viral
ill
risk
factor
acquisit
rsv
piv
influenza
analyz
season
male
sex
transplant
type
associ
increas
risk
develop
rsv
infect
unrel
donor
statu
associ
piv
infect
season
femal
sex
underli
malign
associ
increas
risk
influenza
infect
data
studi
suggest
lymphopenia
also
enhanc
risk
acquisit
respiratori
viral
ill
dosedepend
fashion
lymphopenia
also
associ
increas
risk
progress
lower
respiratori
tract
diseas
steroid
note
protect
progress
influenza
infect
risk
factor
dosedepend
manner
progress
piv
infect
chakrabarti
et
al
ljungman
et
al
nichol
et
al
hsct
recipi
rvi
typic
develop
upper
respiratori
tract
infect
initi
smaller
percentag
progress
lower
respiratori
tract
involv
median
day
unfortun
yet
possibl
determin
accur
patient
progress
lower
tract
diseas
rsv
recogn
one
highest
rate
progress
lower
respiratori
tract
patient
develop
rsv
first
month
posttranspl
median
onset
rang
day
posttranspl
falsey
walsh
patient
typic
present
cough
fever
rhinorrhea
sinu
congest
less
frequent
sore
throat
otalgia
larg
percentag
patient
rale
rhonchi
exam
chest
xray
infiltr
manifest
wheez
dyspnea
rsv
progress
pneumonia
clear
prospect
data
direct
manag
sever
mostli
small
retrospect
studi
document
poor
respons
intraven
ribavirin
alon
surviv
combin
aerosol
ribavirin
surviv
without
surviv
ivig
lewinsohn
et
al
ljungman
et
al
better
result
document
aerosol
ribavirin
alon
surviv
harrington
et
al
ljungman
et
al
combin
ivig
surviv
ghosh
et
al
ljungman
et
al
whimbey
et
al
rsvig
surviv
devincenzo
et
al
small
et
al
palivizumab
data
suggest
optim
therapi
rsv
pneumonia
involv
combin
aerosol
ribavirin
plu
antibodi
prepar
start
antivir
therapi
earli
impact
surviv
combin
therapi
start
respiratori
failur
begin
patient
surviv
compar
none
therapi
begun
respiratori
failur
potenti
risk
factor
increas
mortal
patient
rsv
pneumonia
includ
copathogen
concomit
immunosuppress
steroid
antilymphocyt
antibodi
lymphopenia
preexist
lung
diseas
therapi
use
includ
time
onset
prevent
strategi
explor
limit
frequenc
rsv
diseas
infect
control
import
compon
prevent
infect
limit
valu
patient
leav
hospit
clinic
use
rsvig
palivizumab
prophylaxi
might
benefici
although
two
prepar
never
studi
popul
random
fashion
would
expens
use
preemptiv
therapi
aerosol
ribavirin
could
use
patient
asymptomat
shed
rsv
uri
although
earli
detect
method
limit
abil
implement
preemptiv
manag
infect
addit
preemptiv
strategi
test
rsv
random
trial
result
potenti
devast
outcom
rsv
rvi
concern
need
delay
hsct
symptomat
patient
retrospect
case
seri
patient
underw
autolog
hsct
advanc
multipl
myeloma
also
activ
rsv
uri
none
patient
progress
lri
requir
transfer
icu
die
transplant
result
rsv
aslan
et
al
one
patient
develop
tracheobronch
requir
oxygen
transient
strategi
current
use
delay
transplant
upper
respiratori
symptom
present
transplant
cessat
symptom
nasal
wash
neg
viru
cdc
fhcrc
found
patient
develop
rsv
uri
prior
transplant
thirtyon
uri
condit
two
develop
pneumonia
transplant
respons
treatment
six
discov
start
condit
three
transplant
abort
none
develop
rsv
pneumonia
wherea
two
continu
transplant
develop
pneumonia
one
die
studi
document
pretranspl
shed
patient
day
patient
shed
viru
least
month
delay
transplant
result
progress
underli
diseas
thu
delay
transplant
least
month
advis
myeloabl
transplant
cdc
current
studi
design
assess
clinic
microbiolog
characterist
rsv
infect
patient
hematolog
malign
adult
inand
outpati
hematolog
malign
includ
hsct
recipi
includ
studi
sign
symptom
upper
lower
respiratori
tract
infect
total
nasopharyng
aspir
bronchoalveolar
lavag
collect
episod
respiratori
infect
patient
octob
june
one
multipl
respiratori
virus
identifi
episod
influenza
viru
found
case
follow
respiratori
syncyti
viru
enterovirus
adenovirus
influenza
b
viru
parainfluenza
virus
piv
piv
two
rhinovirus
eight
case
mix
viral
infect
diagnos
among
episod
rsv
infect
rsv
detect
alon
eight
patient
also
infect
influenza
one
cmv
patient
clear
infect
first
week
one
patient
detect
viru
day
week
thirtyeight
percent
patient
acquir
rsv
infect
hospit
median
day
rang
day
upper
respiratori
tract
infect
diagnos
patient
lri
one
patient
upper
respiratori
tract
infect
present
progress
lri
six
patient
receiv
inhal
ribavirin
one
treat
patient
die
studi
prospect
confirm
rsv
occur
typic
winter
month
nosocomi
transmit
frequent
progress
involv
lower
airway
patient
clear
infect
first
week
infect
rsv
infect
associ
low
mortal
heterogen
popul
despit
lower
respiratori
tract
symptom
tuoma
jartti
univers
turku
turku
finland
children
least
one
episod
wheez
case
asthma
exacerb
result
viral
respiratori
infect
glezen
et
al
habbick
et
al
hesselmar
et
al
johnston
et
al
martinez
et
al
mcintosh
mertsola
et
al
rake
et
al
prospect
studi
conduct
determin
respiratori
virus
isol
children
finland
hospit
acut
expiratori
wheez
total
hospit
children
median
age
year
rang
month
year
recruit
septemb
may
turku
finland
patient
chronic
lung
diseas
heart
diseas
chronic
steroid
use
exclud
studi
addit
serolog
nasal
aspir
test
pcr
rhino
entero
coronaand
metapneumoviru
hmpv
antigen
detect
cultur
influenza
b
parainfluenza
type
adenoviru
rsv
cultur
rhinoand
enteroviru
potenti
caus
viral
agent
found
case
rsv
nontyp
adenoviru
hmpv
parainfluenza
type
influenza
b
coronaviru
eighteen
percent
patient
multipl
virus
detect
patient
rhinoand
entrovirus
slightli
older
median
year
patient
rsv
hmpv
infect
median
year
patient
rsv
hmpv
typic
longer
durat
hospit
patient
viral
pathogen
detect
rvi
associ
almost
episod
wheez
lead
hospit
studi
studi
also
one
first
demonstr
contribut
hmpv
particularli
winter
epidem
correl
wheez
jartti
et
al
van
den
hoogen
et
al
preval
enteroviru
higher
studi
previous
report
result
confirm
larg
contribut
picornavirus
particularli
rhinovirus
wheez
episod
children
subbarao
niaid
nih
bethesda
md
one
mani
key
compon
pandem
prepared
develop
pandem
vaccin
pandem
arriv
liveattenu
influenza
vaccin
laiv
particularli
appeal
typic
easier
deliv
inject
vaccin
unfortun
sever
issu
current
limit
develop
vaccin
includ
need
gener
candid
vaccin
facil
wide
rang
avian
virus
choic
vaccin
develop
strategi
revers
genet
reassort
choic
donor
viru
laiv
need
extens
safeti
immunogen
test
candid
anim
human
addit
issu
select
optim
serolog
assay
hai
nt
srh
determin
immunogen
defin
appropri
protect
titer
avian
influenza
subtyp
recent
identifi
high
prioriti
pandem
vaccin
develop
three
candid
vaccin
earli
state
develop
aa
candid
vaccin
modifi
hk
coldadapt
reassort
viru
develop
revers
genet
part
collabor
aviron
cdc
viru
replic
log
egg
mutagen
ha
decreas
cleavabl
endogen
proteas
viru
grow
c
c
pathogen
chicken
ferret
studi
chicken
demonstr
two
candid
vaccin
immunogen
reduc
mortal
challeng
vaccin
temperaturesensit
coldadapt
reassort
viru
gener
genet
reassort
spf
egg
part
collabor
nih
cdc
mous
studi
intranas
applic
reassort
viru
result
low
titer
viru
nose
minim
viru
lung
vaccin
also
immunogen
mice
prevent
challeng
infect
final
aa
coldadapt
viru
develop
also
genet
reassort
part
collabor
nih
cdc
creat
earli
studi
candid
ongo
first
two
vaccin
move
human
proofofprincipl
trial
trial
conduct
isol
volunt
vaccin
summer
influenza
activ
minim
unit
state
key
properti
vaccin
studi
includ
infect
level
attenu
immunogen
hope
futur
studi
allow
develop
seed
lot
vaccin
virus
rang
avian
virus
addit
altern
substrat
vaccin
product
new
adjuv
need
test
enhanc
armamentarium
pandem
influenza
strain
trival
coldadapt
influenza
vaccin
caivt
test
wyeth
laboratori
major
advantag
stabl
liquid
form
without
need
freez
studi
design
determin
efficaci
caivt
divers
asian
popul
children
age
month
cultureconfirm
influenza
ill
assess
efficaci
serial
influenza
season
investig
impact
caivt
acut
otiti
media
subject
blindli
random
fashion
receiv
either
caivt
placebo
first
year
studi
booster
dose
given
day
initi
dose
third
dose
given
year
first
four
studi
group
caivt
year
dose
caivt
year
dose
caivt
year
caivtcaivtplacebo
placeboplacebocaivt
placeboplaceboplacebo
studi
enrol
healthi
children
age
month
whose
parent
legal
guardian
gave
written
consent
tabl
efficaci
vaccin
cultureconfirm
ill
estim
ci
overal
point
estim
efficaci
b
influenza
infect
respect
interim
analysi
first
year
data
appear
caivt
confer
substanti
efficaci
cultureconfirm
influenza
asian
children
despit
region
differ
influenza
circul
addit
data
impact
aom
result
second
year
studi
progress
harri
greenberg
medimmun
vaccin
mt
view
ca
editori
note
flumist
intranas
liveattenu
coldadapt
trival
influenza
vaccin
approv
fda
use
healthi
children
adult
age
year
june
approv
caivt
vaccin
slow
concern
safeti
efficaci
certain
age
group
vaccin
shown
genet
stabl
virus
lost
temperatur
sensit
coldadapt
rna
viru
virosom
recov
vaccin
patient
likewis
transmiss
vaccin
viru
infrequ
one
case
document
child
day
care
set
acquir
vaccin
strain
anoth
vaccin
child
child
inadvert
acquir
viru
symptom
distinct
placebo
recipi
two
major
concern
part
fda
initi
advisori
panel
review
relat
question
increas
risk
pneumonia
asthma
vaccin
individu
subsequ
analys
origin
clinic
trial
data
fail
demonstr
increas
risk
pneumonia
vaccin
individu
data
larg
studi
northern
california
kaiser
system
demonstr
increas
number
medic
encount
asthma
vaccin
children
compar
placebo
vaccin
patient
visit
outpati
clinic
visit
asthma
manag
tempor
cluster
within
postvaccin
observ
period
mani
subject
histori
asthma
time
enrol
none
requir
hospit
asthma
signal
detect
children
age
year
fda
advisori
committe
felt
adequ
data
efficaci
safeti
vaccin
children
month
age
adult
younger
recommend
approv
age
group
result
studi
need
age
group
complet
studi
includ
young
children
otherwis
healthi
adult
age
year
virosom
function
reconstitut
noninfecti
viral
envelop
retain
cell
entri
properti
nativ
viru
lack
rna
core
effect
virosom
repres
function
reconstitut
hemagglutinin
ha
one
key
differ
viru
envelop
virosom
virosom
ha
molecul
extend
bidirect
extern
intern
surfac
membran
fig
virosom
produc
first
solubil
inactiv
influenza
viru
excess
nonion
deterg
octaethyleneglyconndodecyl
monoeth
stegmann
et
al
sever
theoret
advantag
virosom
vaccin
virosom
maintain
normal
receptor
bind
lowphdepend
membran
fusion
occur
intact
influenza
virus
antigen
may
also
encapsul
within
lumen
virosom
deliveri
antigen
occur
intracellularli
immun
system
react
antigen
within
virosom
theoret
taken
antigen
present
cell
apc
virosom
would
fuse
within
acid
endosom
cell
compart
result
deliveri
virosomeencapsul
antigen
cell
cytosol
surfaceassoci
antigeninclud
part
hawould
remain
behind
endosom
cytosol
antigen
would
process
proteasom
peptid
produc
would
bind
er
mhc
class
molecul
ultim
present
apc
surfac
prime
cell
matur
cytotox
lymphocyt
ctl
within
endosom
virosom
antigen
would
degrad
allow
peptid
bind
mhc
class
ii
molecul
activ
helper
cell
fig
document
abil
virosom
activ
mhc
class
ii
mediat
immun
pathway
ovalbumin
includ
within
virosom
ovalbumincontain
virosom
incub
along
cultur
murin
dendrit
cell
presenc
cell
vitro
assay
mhc
class
class
ii
present
use
specif
cell
experi
repeat
fusioninactiv
ovalbumin
virosom
fusionact
ovalbumin
virosom
fusioninact
ovalbumin
virosom
empti
virosom
free
ovalbumin
result
effici
antigen
present
via
mhc
pathway
fusionact
fusioninact
ovalbumin
virosom
access
mhc
ii
pathway
bungen
et
al
accordingli
vivo
mous
model
fusionact
ovalbumincontain
virosom
induc
power
class
mhcrestrict
ctl
respons
ovalbumin
antigen
bungen
et
al
despit
concern
preexist
antibodi
ha
would
block
virosomemedi
ctl
prime
mice
high
preexist
antibodi
titer
virosom
ha
develop
strong
ovalbuminspecif
ctl
respons
subsequ
immun
ovalbumincontain
virosom
appear
antibodyopson
virosom
activ
process
dendrit
cell
uptak
via
fc
receptor
conclus
virosom
deliv
antigen
dendrit
cell
present
mhc
class
ii
molecul
fusion
activ
virosom
essenti
mhc
class
present
virosom
induc
matur
dendrit
cell
evidenc
upregul
matur
marker
includ
mhc
class
ii
molecul
although
virosom
induc
mix
respons
respons
skew
toward
support
prime
ctl
activ
result
broad
activ
immun
system
abil
carri
antigen
virosom
hold
signific
promis
vaccin
develop
virosom
could
also
use
platform
inclus
immunomodul
adjuv
use
potenti
intranas
andor
pandem
influenza
vaccin
newer
influenza
virosom
vaccin
could
supplement
influenza
antigen
np
induct
humor
ctl
respons
potenti
applic
includ
vaccin
develop
bioterror
agent
therapeut
cancer
vaccin
hope
virosom
influenza
vaccin
initi
develop
berna
biotech
develop
solvay
pharmaceut
clinic
avail
influenza
season
netherland
switzerland
fifteen
clinic
studi
patient
done
vaccin
call
influvac
vaccin
well
toler
least
effect
convent
subunit
vaccin
vaccin
result
seroprotect
seroconvers
patient
age
year
respect
fluinsur
tm
trival
subunit
influenza
vaccin
intranas
inocul
compos
inactiv
partiallypurifi
influenza
antigen
noncoval
complex
proteosom
tm
adjuvantdeliveri
system
vaccin
incorpor
influenza
antigen
neisseria
meningitidi
outer
membran
protein
omp
predominantli
porin
b
otherwis
known
class
ii
omp
process
proteosom
tm
protein
leav
nucleic
acid
n
meninigitidi
lipopolysaccharid
final
product
process
shown
adapt
egggrown
detergentsplit
antigen
inactiv
either
formalin
also
use
recombin
antigen
gener
baculoviru
system
fluinsur
tm
vaccin
stabl
mous
immunogen
ha
quantit
singl
radial
immunodiffus
srid
assay
year
c
least
month
room
temperatur
although
initi
formul
thimeros
preservativefre
filter
product
packag
unit
dose
devic
develop
mice
nasallyadminist
fluinsur
tm
induc
serum
igg
serum
hai
antibodi
respons
equal
greater
dose
influenza
antigen
alon
given
im
addit
intranas
fluinsur
tm
induc
nasal
lung
wash
virusspecif
iga
wherea
minim
iga
detect
follow
im
vaccin
intranas
influenza
antigen
alon
may
induc
secretori
respons
fluinsur
tm
order
magnitud
superior
addit
fluinsur
tm
associ
ratio
suggest
respons
similar
viru
infect
correl
observ
spleen
cell
anim
immun
nasal
fluinsur
tm
produc
amount
anim
immun
im
vaccin
restimul
viru
vitro
much
less
cytokin
fluinsur
tm
protect
mice
lethal
respiratori
challeng
mouseadapt
homolog
viru
manner
indistinguish
im
vaccin
also
protect
ferret
fever
andor
viru
shed
follow
challeng
recent
epidem
strain
anim
toxic
studi
demonstr
productrel
clinic
toxic
cn
includ
olfactori
bulb
patholog
total
adult
enrol
five
clinic
trial
monoval
prototyp
trival
fluinsur
tm
date
activ
placebo
control
monoval
prototyp
trival
data
highli
consist
regard
immunogen
safeti
signific
safeti
issu
reactogen
significantli
relat
vaccin
formul
shortliv
day
median
mild
nasal
congest
clear
scanti
rhinorrhea
nasal
symptom
occur
vaccine
subject
receiv
activ
treatment
fever
hypersensit
fluinsur
tm
regimen
contain
least
one
dose
g
influenza
ha
induc
threeto
fivefold
increas
serum
hai
gmt
among
subject
previous
suscept
hai
viru
question
subject
seroconvert
day
regimen
test
induc
least
transient
rise
nasal
antibodi
level
singledos
regimen
induc
approxim
twofold
increas
geometr
mean
level
twodos
regimen
induc
increas
except
lowest
singledos
regimen
nasal
antibodi
level
persist
elev
geometr
mean
level
followup
overal
immun
respons
influenza
antigen
quit
consist
across
multipl
studi
lot
wherea
respons
b
antigen
mani
influenza
vaccin
variabl
trival
studi
perform
date
potenti
protect
immun
respons
seen
strain
strain
b
strain
summari
fluinsur
tm
proteosom
intranas
influenza
vaccin
appear
promis
candid
inexpens
easili
adapt
new
virus
appear
safe
immunogen
anim
human
control
studi
protect
efficaci
vaccin
ongo
reinhard
berna
biotech
ltd
bern
switzerland
one
commerci
parenter
administ
virosom
influenza
vaccin
call
inflex
v
licens
switzer
land
current
avail
countri
worldwid
studi
adult
demonstr
inflex
v
equal
convent
inactiv
influenza
vaccin
fluarix
term
immunogen
appear
better
toler
new
virosom
vaccin
adjuv
current
develop
adjuv
vaccin
test
hiv
children
immun
respons
frequent
children
among
hiv
children
seroprotect
serum
antibodi
respons
document
b
respect
seroconvers
note
respect
final
nonvirosom
intranas
influenza
vaccin
use
escherichia
coli
heatlabil
toxin
adjuv
previous
manufactur
berna
remov
market
possibl
associ
bell
palsi
epidemiolog
investig
compar
frequenc
bell
palsi
commerci
im
vaccin
patient
berna
vaccin
patient
two
im
five
patient
bell
palsi
although
incid
low
compani
decid
remov
product
market
rsva
subunit
vaccin
contain
f
g
protein
formul
alum
adjuv
intramuscular
inject
develop
recent
target
popul
vaccin
elderli
highrisk
adult
preliminari
studi
immunogen
toler
undertaken
healthi
adult
age
year
random
activ
vaccin
evalu
month
random
alumplacebo
group
evalu
frequent
advers
effect
vaccin
includ
pain
tender
tend
resolv
within
h
data
antif
antig
antibodi
titer
summar
tabl
although
titer
declin
time
level
month
vaccin
individu
consist
baselin
studi
show
vaccin
safe
immunogen
although
annual
vaccin
would
like
requir
maintain
protect
antibodi
level
followup
studi
gave
activ
vaccin
vaccine
placebo
tabl
immunogen
rsva
subunit
vaccin
given
month
first
vaccin
log
geometr
mean
titer
fourfold
increas
titer
recipi
first
studi
month
initi
vaccin
shown
tabl
antibodi
titer
decreas
time
revaccin
immunogen
suggest
annual
vaccin
may
allow
mainten
protect
antibodi
clinic
trial
vaccin
underway
recombin
chimer
protein
compris
bb
albumin
bind
domain
streptococc
protein
g
residu
rsva
long
strain
g
protein
express
e
coli
preclin
studi
found
formul
alum
immunogen
protect
rsva
b
challeng
immunogen
protect
murin
neonat
even
presenc
high
antirsv
matern
antibodi
titer
brandt
et
al
siegrist
et
al
induc
evid
enhanc
patholog
corvaia
et
al
plotnickygilquin
et
al
power
et
al
protect
via
antibodi
cell
plotnickygilquin
et
al
power
et
al
doseescal
phase
studi
healthi
young
adult
age
year
old
demonstr
alum
welltoler
immunogen
demonstr
specif
antibodi
respons
follow
intramuscular
im
inject
power
et
al
inde
subject
three
vaccin
group
twofold
igg
antibodi
rise
furthermor
subject
twofold
increas
viru
neutral
vn
titer
g
dose
dose
g
demonstr
similar
immunogen
g
induc
lower
respons
apart
slight
increas
vn
titer
follow
second
dose
appar
advantag
give
dose
vaccin
result
sever
advers
event
patient
mild
pain
red
edema
inject
site
develop
fever
follow
vaccin
phase
ii
studi
ambulatori
elderli
adult
age
year
undertaken
determin
dose
regimen
use
phase
iii
efficaci
trial
patient
random
blind
fashion
dose
g
placebo
administ
im
either
twice
interv
frequent
advers
effect
vaccin
local
reaction
consist
mainli
pain
much
lesser
extent
local
red
indur
edema
oral
temperatur
c
observ
four
individu
tendenc
reaction
highest
vaccin
dose
second
inject
one
case
flulik
syndrom
record
transient
rise
hepat
enzym
two
case
hypersensit
type
iiilik
reaction
also
record
rapidli
resolv
within
day
sequela
overal
toler
profil
favor
independ
expert
board
recommend
clinic
develop
continu
increas
safeti
document
phase
iii
efficaci
studi
expect
antibodi
respons
lower
elderli
previous
observ
healthi
young
adult
nonetheless
subject
demonstr
least
twoand
fourfold
rise
antibodi
titer
respect
month
postvaccin
depend
group
furthermor
subject
also
demonstr
twofold
vn
titer
increas
doserespons
evid
three
dose
test
boost
evid
follow
second
dose
followup
gm
antibodi
titer
drop
progress
month
subject
return
baselin
titer
conclus
data
indic
alum
immunogen
elderli
singl
dose
regimen
probabl
suffic
howev
safeti
monitor
would
essenti
compon
phase
iii
efficaci
studi
peter
wright
vanderbilt
univers
medic
center
nashvil
tn
rsv
affect
children
first
year
life
respons
hospit
death
per
year
children
addit
cost
attribut
rsv
infect
calcul
us
million
per
year
although
children
risk
factor
mani
children
infect
sever
enough
requir
hospit
born
prematur
congenit
heart
diseas
bronchopulmonari
dysplasia
rsv
caus
ill
decemb
march
account
uri
among
communitydwel
children
lri
help
combat
diseas
coldpassag
liveattenu
vaccin
creat
use
revers
genet
result
sh
temperaturesensit
attenu
viru
use
vaccin
unscreen
adult
rsv
seroposit
children
month
old
rsv
seroneg
children
month
infant
initi
dose
adult
seroposit
children
recover
viru
recover
viru
titer
quit
low
log
seroneg
children
shed
viru
nasal
secret
peak
viral
titer
log
seroneg
children
ceas
shed
within
day
altern
vaccin
sh
viru
also
test
found
lower
rate
infect
titer
shed
addit
test
attenu
strain
show
increas
initi
vaccin
inoculum
titer
substanti
increas
viral
shed
immunogen
final
studi
children
less
month
old
show
compar
level
viral
shed
presenc
absenc
matern
antibodi
young
infant
minim
antibodi
respons
although
detect
serum
level
igg
iga
g
protein
mucos
antibodi
produc
far
lower
level
seen
children
older
month
age
second
dose
vaccin
respons
use
surrog
reinfect
result
rare
shed
viru
evid
enhanc
rsv
ill
infect
find
suggest
vaccin
may
protect
without
detect
increas
antibodi
level
final
protein
delet
viru
chang
may
make
viru
suscept
interferon
found
markedli
reduc
viral
shed
particularli
seroneg
children
compar
attenu
vaccin
strain
although
studi
liveattenu
vaccin
rsv
given
limit
inform
efficaci
given
signific
data
support
continu
develop
vaccin
parainfluenza
viru
type
frequent
caus
infect
young
children
one
studi
found
children
year
age
experienc
infect
children
age
month
children
age
month
later
reinfect
strain
suggest
incomplet
protect
follow
primari
infect
glezen
et
al
two
differ
vaccin
current
develop
goal
prevent
pivassoci
lower
respiratori
tract
ill
risk
liveattenu
bovin
vaccin
develop
medimmun
nih
vaccin
develop
cooper
wyeth
nih
although
bovin
well
toler
use
vaccin
infant
children
vaccin
children
develop
fourfold
rise
antibodi
titer
far
less
would
seen
natur
infect
reciproc
mean
preand
postvaccin
hai
titer
test
antigen
respect
vaccine
respect
vaccine
determin
compon
respons
attent
revers
genet
use
creat
array
variant
singl
bovin
gene
replac
recombin
strain
result
improv
antibodi
respons
afford
protect
rel
monkey
two
chimer
virus
b
h
hn
h
felt
strongest
candid
plan
made
test
virus
human
addit
potenti
use
recombin
virus
vector
express
rsv
f
g
protein
measl
h
protein
surfac
glycoprotein
respiratori
virus
durbin
et
al
schmidt
et
al
schmidt
et
al
skiadopoulo
et
al
tao
et
al
anoth
attenu
viru
develop
vaccin
viru
grown
vero
cell
serial
passag
low
temperatur
agmk
result
viru
coldadapt
temperaturesensit
attenu
human
nonhuman
primat
result
viru
grow
well
temperatur
c
characterist
theoret
limit
replic
upper
airway
phase
studi
adult
seroposit
children
month
intranas
inocul
log
pfu
result
infect
adult
seroposit
children
suggest
prior
natur
infect
limit
infecti
vaccin
viru
phase
studi
seroneg
children
given
either
log
pfu
success
infect
infect
mean
peak
titer
shed
viru
log
pfuml
studi
vaccin
well
toler
without
signific
advers
effect
although
small
number
uri
increas
number
otiti
media
episod
observ
phase
phase
ii
studi
next
twodos
studi
infant
conduct
second
dose
use
surrog
challeng
infect
first
dose
vaccin
well
toler
similar
frequenc
fever
congest
lri
om
occur
vaccin
unvaccin
children
children
revaccin
month
first
exposur
much
less
shed
vaccin
viru
second
dose
patient
receiv
second
dose
month
first
viru
shed
detect
greater
frequenc
challeng
vaccin
result
signific
rise
serum
iga
antihn
children
result
signific
hai
titer
chang
five
children
temperaturesensit
intermedi
virus
recov
followup
five
form
plaqu
c
repres
small
fraction
total
viral
popul
present
peak
viral
shed
clear
rate
fulli
temperaturesensit
virus
associ
chang
clinic
statu
studi
clear
vaccin
welltoler
immunogen
infant
children
uncommonli
may
partial
revert
multipl
dose
need
infanc
interv
dose
month
result
posit
find
rsva
cpt
vaccin
test
alon
combin
vaccin
random
doubleblind
studi
healthi
children
dualli
seroneg
rsv
neutral
antibodi
hai
children
given
either
rsv
placebo
vaccin
contain
pfu
vaccin
viru
ml
fever
occur
otiti
media
rsv
placebo
group
respect
four
children
fever
c
shed
rsv
percent
infect
rsv
use
sole
vaccin
given
combin
vaccin
infect
rsv
infect
combin
vaccin
induc
lower
titer
antibodi
viru
given
alon
antibodi
respons
vaccin
list
tabl
conclus
major
children
respond
rsv
combin
vaccin
interfer
two
viru
vaccin
evid
children
studi
plan
investig
incid
om
util
two
dose
combin
vaccin
liveattenu
vaccin
liv
creat
use
genet
reassort
epidem
strain
three
attenu
master
strain
current
trival
vaccin
contain
b
influenza
strain
intranas
administ
vaccin
shown
previous
safe
well
toler
adult
children
children
typic
receiv
two
dose
vaccin
week
apart
adult
get
singl
vaccin
investig
respons
vaccin
children
age
year
old
openlabel
studi
enrol
children
two
influenza
season
receiv
intranas
trival
liv
patient
interview
month
assess
acut
respiratori
infect
vaccin
well
toler
children
uncommonli
develop
fever
headach
sore
throat
fourfold
rise
serum
influenzaspecif
antibodi
children
b
antigen
respect
fourfold
rise
iga
titer
children
respect
reduct
influenza
infect
reduct
acut
respiratori
infect
among
vaccin
children
compar
histor
control
likewis
vaccin
effect
prevent
otiti
media
effect
prevent
bronchiti
liv
current
use
russian
appear
safe
well
toler
effect
children
year
old
subunit
whole
viru
vaccin
healthi
adult
maria
zambon
public
health
laboratori
london
uk
follow
highli
pathogen
avian
influenza
outbreak
hong
kong
enhanc
surveil
identifi
widespread
preval
viru
asian
swine
herd
livebird
market
two
children
develop
influenza
caus
strain
hong
kong
viru
exhibit
receptorbind
properti
consist
human
influenza
virus
suggest
viru
could
potenti
caus
pandem
inactiv
subunit
vaccin
protect
mice
sinc
whole
viru
vaccin
may
immunogen
patient
whole
virion
wv
subunit
sv
vaccin
prepar
use
influenza
ahong
vaccin
use
observerblind
doserang
studi
healthi
adult
age
year
old
volunt
receiv
either
vaccin
contain
g
ha
time
enrol
day
later
antibodi
respons
day
detect
hemagglutin
inhibit
hi
microneutr
mn
singl
radial
hemolysi
srh
vaccin
well
toler
although
wv
associ
frequent
pain
versu
nausea
versu
arthalgia
versu
sv
differ
seroconvers
wv
sv
day
although
seroconvers
like
patient
receiv
g
particularli
wv
patient
younger
year
less
like
convert
first
dose
follow
second
dose
suggest
booster
dose
requir
patient
younger
year
treat
common
cold
echinacea
beyond
ronald
turner
univers
virginia
charlottesvil
va
echinacea
one
wide
use
herbal
remedi
common
cold
despit
frequent
use
echinacosid
addit
polysaccharid
alkamid
present
plant
immunostimulatori
activ
ascrib
polysaccharid
antiinflammatori
activ
ascrib
caffeic
acid
deriv
alkamid
biolog
activ
constitu
differ
among
three
speci
tabl
unfortun
content
biolog
activ
compon
plant
depend
harvest
time
part
plant
use
avail
prepar
use
differ
speci
differ
part
plant
plant
differ
region
harvest
time
result
signific
variabl
content
cichor
acid
alkamid
differ
brand
differ
lot
brand
studi
agent
difficult
unclear
optim
dose
formul
echinacea
use
rel
absorpt
distribut
prepar
prospect
studi
echinacea
common
cold
standard
echinacea
extract
contain
cichor
acid
echinacosid
alkamid
prepar
sixtythre
patient
ingest
activ
agent
placebo
week
prior
challeng
rhinoviru
type
rhinoviru
infect
occur
echinaceatr
placebotr
volunt
insignific
differ
likewis
differ
symptom
two
group
prepar
echinacea
prevent
lessen
sever
rhinoviru
cold
summari
activ
echinacea
extract
unclear
product
standard
current
avail
studi
provid
limit
data
gener
differ
product
compon
pathogenesi
rhinovir
cold
need
consid
target
therapeut
intervent
viru
infect
nasal
epithelium
result
cellular
oxid
stress
nonspecif
host
inflammatori
respons
result
sore
throat
vasodil
serum
transud
event
turn
result
nasal
obstruct
rhinorrhea
progress
viru
lower
respiratori
tract
may
also
occur
one
step
amen
modif
may
oxid
stress
induc
viru
cell
line
expos
rsv
exposur
antioxid
dmso
result
reduc
product
concentrationdepend
manner
investig
role
oxid
stress
rhinoviru
infect
carbonyl
dcfda
stain
use
document
oxid
stress
cell
line
expos
rhinoviru
next
nacetylcystein
nac
anoth
potent
antioxid
use
cell
line
expos
hrv
nac
exposur
associ
signific
decreas
nfb
concentrationdepend
manner
elucid
role
variou
agent
manag
rhinovir
cold
antiicam
antibodi
studi
determin
impact
cytokin
product
antiicam
exposur
cell
cultur
associ
signific
decreas
viral
titer
differ
product
well
expos
unexpos
antiicam
suggest
elabor
independ
viral
bind
icam
sever
oxidas
inhibitor
includ
diphenylen
iodonium
dpi
ibuprofen
allopurinol
rotenon
test
similar
cell
cultur
system
determin
impact
rhinovir
replic
product
dpi
appear
reduc
viral
titer
addit
test
found
dpi
success
reduc
product
respons
rsv
coronaviru
infect
well
sinc
dpi
specif
inhibitor
nadphoxidas
addit
studi
conduct
determin
compon
oxidas
respons
reduct
titer
first
cgd
skin
fibroblast
defici
compon
napdhoxidas
infect
hrv
differ
viral
titer
product
compar
normal
skin
fibroblast
fibroblast
defici
reduc
product
lastli
antisens
molecul
use
assess
role
product
presenc
antisens
construct
level
markedli
reduc
amplif
cell
line
look
specif
nadphlik
oxidas
found
present
test
cell
line
futur
studi
direct
specif
inhibitor
assess
abil
limit
viral
titer
symptom
result
infect
human
rhinoviru
hrv
use
receptor
attach
respiratori
epithelium
greve
et
al
tomassini
et
al
past
two
differ
compound
develop
bind
either
block
bind
solubl
found
prevent
treat
experiment
hrv
infect
adult
unfortun
given
high
dose
six
time
day
effect
pursu
clinic
develop
huguenel
et
al
turner
et
al
murin
monoclon
antibodi
term
rrma
block
found
safe
human
partial
effect
prevent
experiment
hrv
infect
one
trial
hayden
et
al
vitro
investig
rrma
show
kinet
respect
receptor
interact
favor
particular
k
hrv
rrma
respect
wherea
k
respect
kinet
show
rrma
avid
insuffici
compet
effect
hrv
sinc
multival
antibodi
increas
bind
affin
decreas
k
construct
tetramer
recombin
rrma
antibodi
four
arm
molecul
call
coldsol
tm
three
domain
human
rrma
fab
flexibl
linker
tetramer
domain
gene
antibodi
construct
use
transform
e
coli
produc
homogen
tetram
ultracentrifug
bind
kinet
studi
done
cell
k
bind
halflif
greater
h
vitro
experi
use
hela
primari
human
lung
cell
demonstr
nanomolar
concentr
drug
effect
prevent
hrv
replic
cytopath
effect
molecul
stabl
month
c
week
nasal
mucu
c
result
promis
studi
compound
develop
intranas
antirhinoviru
agent
addit
preclin
studi
ongo
plan
clinic
trial
develop
cyanovirinn
cvn
amino
acid
protein
isol
cyanobacterium
nostoc
ellipsosporum
antivir
activ
human
immunodefici
viru
chang
bewley
cvn
activ
vitro
influenza
littl
activ
adenoviru
parainfluenza
viru
respiratori
syncyti
viru
enteroviru
rhinoviru
coxsacki
viru
inhibit
straindepend
sever
strain
influenza
influenza
b
highli
resist
cvn
much
less
cvn
bind
resist
sensit
asydney
viru
consist
antivir
activ
observ
cell
cultur
studi
led
bind
experi
use
purifi
ha
abeij
viru
europiumlabel
cvn
bound
viral
ha
contain
high
mannos
residu
exogen
could
inhibit
bind
cvn
ha
virucid
assay
pool
stock
viru
incub
cvn
min
prior
viru
titrat
cell
found
anw
virus
resist
virucid
effect
mouseadapt
virus
ashangdong
aduck
agul
bhong
kong
much
resist
compound
cellcultur
passag
virus
chang
found
mouseadapt
ashangdong
result
loss
high
mannos
glycosyl
site
posit
viral
hemagglutinin
thu
respons
viral
resist
cvn
conclus
interact
cvn
influenza
hemagglutinin
carbohydratemedi
cvn
discrimin
bind
glycoprotein
express
highmannos
oligosaccharid
viru
resist
cvn
correl
loss
glycosyl
site
viral
hemagglutinin
ruprintrivir
ami
patick
pfizer
global
research
develop
la
jolla
ca
search
drug
activ
picornavirus
proteas
identifi
import
target
lack
similar
human
proteas
essenti
replic
highli
conserv
activ
site
matthew
et
al
ruprintrivir
current
investig
highli
potent
mean
test
serotyp
nm
peptidomimet
irrevers
proteas
inhibitor
dragovich
et
al
dragovich
et
al
b
patick
et
al
phase
trial
demonstr
ruprintrivir
minim
treatmentrel
advers
nasal
effect
high
nasal
mucu
concentr
ruprintrivir
h
intranas
inocul
phase
ii
studi
volunt
inocul
either
hank
subject
random
receiv
intranas
ruprintrivir
mg
placebo
spray
prophylaxi
time
daili
time
per
day
time
per
day
day
start
h
infect
treatment
time
per
day
day
start
h
infect
patient
receiv
activ
drug
treatment
lower
symptom
score
begin
day
infect
treat
patient
also
lower
viral
titer
cultur
rtpcr
day
prophylaxi
also
reduc
viral
shed
mean
auc
viru
titer
significantli
reduc
frequenc
cold
studi
establish
intranas
ruprintrivir
suspens
signific
antivir
activ
experiment
induc
rhinoviru
infect
phase
ii
treatment
trial
patient
natur
cold
symptom
less
h
conduct
patient
receiv
ruprintrivir
bid
tid
placebo
day
unfortun
volunt
picornaviru
document
first
gener
rtpcr
test
studi
found
differ
outcom
treat
untreat
patient
except
picornavirusinfect
patient
enter
studi
within
first
h
symptomolog
result
result
drug
reformul
current
nasal
solut
phase
trial
show
drug
safe
well
toler
phase
ii
studi
current
underway
pleconaril
oral
bioavail
capsidinhibitor
block
uncoat
attach
picornavirus
bind
hydrophob
pocket
within
capsid
broad
activ
picornavirus
two
pivot
phase
three
clinic
trial
conduct
august
novemb
center
unit
state
canada
patient
afebril
cold
symptom
less
h
moder
sever
rhinorrhea
enrol
patient
receiv
pleconaril
mg
bid
day
enrol
total
patient
enrol
trial
rhinoviru
cold
rtpcr
pleconaril
treatment
associ
reduct
ill
durat
day
studi
respect
ill
sever
reduc
differ
began
day
night
sleep
disturb
reduc
cold
medic
reduc
viral
shed
reduc
day
resist
viru
isol
posttreat
subject
show
suscept
pleconaril
reduct
suscept
amino
acid
chang
resist
variant
map
drugbind
pocket
differ
ill
cours
patient
shed
viru
reduc
suscept
pleconaril
mild
moder
nausea
common
among
patient
receiv
pleconaril
versu
clinic
signific
effect
laboratori
safeti
paramet
threeandahalf
percent
women
oral
contracept
develop
menstrual
disord
use
pleconaril
although
increas
incid
pregnanc
women
conclus
pleconaril
found
first
antivir
drug
effect
reduc
durat
sever
rhinovir
cold
well
toler
prophylaxi
studi
launch
enrol
adult
treat
pleconaril
mg
bid
mg
qd
placebo
week
incid
picornavirusconfirm
cold
pleconaril
bid
qd
placebo
respect
treat
patient
also
correspond
approxim
less
function
impair
sleep
disturb
miss
day
school
work
receiv
pleconaril
versu
placebo
safeti
profil
pleconaril
studi
similar
treatment
studi
although
twoto
threefold
increas
rate
menstrual
disord
pleconaril
recipi
compar
placebo
increas
event
began
second
week
prophylaxi
respons
find
addit
test
done
healthi
volunt
document
increas
activ
day
oral
pleconaril
increas
activ
associ
decreas
auc
ethinyl
estradiol
decreas
auc
midazolam
activ
return
normal
level
day
cessat
pleconaril
administr
interest
note
evid
pleconaril
impact
cytochrom
system
preliminari
studi
rat
dog
human
hepatocyt
assay
although
fda
advisori
panel
review
applic
pleconaril
agre
efficaci
concern
drug
interact
develop
antivir
resist
probabl
overthecounterlik
use
approv
generaliz
avail
efficaci
data
higher
risk
person
result
concern
fda
deem
pleconaril
approv
june
current
pleconaril
still
avail
part
compassion
use
program
viropharma
pursu
approv
oral
dosag
form
life
threaten
enterovir
infect
includ
chronic
meningoenceph
myocaridit
neonat
sepsi
addit
hope
reformul
pleconaril
intranas
deliveri
hope
allow
deliveri
drug
site
infect
without
allow
system
absorpt
result
risk
induc
system
current
pharmaceut
interest
compound
activ
respiratori
virus
limit
focu
chronic
diseas
unattract
commerci
opportun
high
standard
requir
obtain
fda
approv
nonlifethreaten
condit
despit
limit
cold
common
reason
see
physician
result
nearli
patient
take
overthecount
medic
antibiot
antivir
agent
activ
rhinovirus
need
may
addit
benefit
reduc
indiscrimin
use
antibiot
result
induct
antimicrobi
resist
describ
earlier
rsv
import
pathogen
infant
elderli
immunocompromis
respons
excess
hospit
us
billion
direct
medic
cost
annual
sever
compound
develop
may
effect
treat
rsv
infect
one
class
compound
inhibit
rsv
replic
affect
function
associ
viral
fusion
f
glycoprotein
janssen
topic
appli
compound
report
ec
rsv
nm
preclin
studi
bristolmy
squibb
oral
bioavail
compound
report
ec
rsv
nm
preclin
studi
viropharma
compound
deliv
small
particl
aerosol
spa
inhal
ec
rsv
nm
complet
phase
studi
broadli
activ
cell
cultur
rsva
b
virus
vitro
time
drug
addit
studi
suggest
drug
present
earli
infect
affect
singl
round
viru
replic
cotton
rat
prophylact
bid
dose
spa
day
result
signific
reduct
lung
viru
titer
fortysix
independ
escap
variant
select
vitro
variant
amino
acid
chang
map
f
glycoprotein
model
chang
crystal
structur
newcastl
diseas
viru
metast
form
f
glycoprotein
indic
amino
acid
chang
map
head
domain
protein
chen
et
al
preclin
toxicolog
studi
adult
rat
adult
dog
neonat
dog
anim
given
week
spa
inhal
result
histolog
chang
genotox
studi
neg
date
ind
new
drug
file
approv
third
quarter
phase
studi
recent
complet
although
data
analysi
ongo
studi
plan
stage
current
mikhail
matrosovich
philipp
univers
marburg
germani
influenza
viru
develop
resist
neuraminidas
inhibitor
via
chang
neuraminidas
na
result
decreas
drug
bind
hemagglutinin
ha
result
lower
ha
affin
cellular
receptor
detect
type
resist
perhap
novel
one
viru
inhibit
assay
cell
cultur
requir
unfortun
current
cell
cultur
assay
predict
influenza
viru
sensit
neuraminidas
inhibitor
nai
enzym
inhibit
assay
vivo
mckimmbreschkin
tisdal
nai
sensit
strain
may
appear
resist
nai
resist
mutant
may
show
suscept
current
method
one
reason
limit
laboratori
cell
line
model
influenza
viru
receptor
human
airway
epithelium
human
airway
epithelium
mostli
two
six
link
sialic
acid
high
receptor
densiti
influenza
viru
infect
highli
na
depend
laboratori
cell
includ
commonli
use
madin
darbi
canin
kidney
mdck
cell
hand
mostli
two
three
link
sialic
acid
low
receptor
densiti
influenza
infect
less
na
depend
creat
cell
line
better
reflect
normal
human
airway
epithelium
mdck
cell
transfect
attach
sialic
acid
transfect
achiev
use
piresneo
vector
gene
result
overexpress
neomycin
resist
preliminari
studi
demonstr
transfect
stabl
result
substanti
increas
two
six
link
sialic
acid
cell
surfac
cell
also
increas
bind
human
influenza
viru
compar
standard
mdck
cell
cell
cultur
studi
mdck
mdck
cell
sensit
nai
siattransfect
cell
mdck
cell
wild
type
isol
initi
treatment
neuraminidas
inhibitor
test
parallel
posttreat
na
mutant
siat
cell
abl
differenti
suscept
resist
viru
mdck
cell
similar
result
note
mutant
drug
suscept
pattern
correl
affin
receptor
virus
summari
siattransfect
mdck
cell
acquir
gene
stabli
express
result
increas
express
sialic
acid
reduc
express
sialic
acid
human
influenza
virus
improv
affin
cell
greater
sensit
nai
cell
cultur
use
transform
cell
sensit
virus
oseltamivir
carboxyl
cell
consist
sensit
na
enzym
assay
ha
receptorbind
phenotyp
transfect
mdck
cell
appear
promis
system
test
influenza
viru
sensit
nai
sequenc
variat
suscept
influenza
viru
clinic
isol
zanamivir
oseltamivir
prior
introduct
clinic
practic
jenni
mckimmbreschkin
csiro
health
scienc
nutrit
parkvil
australia
zanamivir
oseltamivir
specif
inhibit
neuraminidas
na
influenza
b
virus
introduc
clinic
practic
na
mutat
detect
clinic
isol
confer
resist
avail
neuraminidas
inhibitor
nai
includ
confer
resist
oseltamivir
confer
resist
oseltamivir
zanamivir
wetheral
et
al
neuraminidas
inhibitor
suscept
network
nisn
establish
monitor
potenti
develop
resist
clinic
isol
widespread
introduct
na
inhibitor
clinic
practic
zambon
et
al
determin
baselin
sensit
isol
prior
introduct
drug
isol
collect
influenza
surveil
network
differ
region
world
sensit
na
determin
use
enzym
inhibit
assay
preliminari
test
show
munana
fluoresc
assay
potier
et
al
nastar
chemiluminesc
assay
buxton
et
al
gave
similar
result
although
nastar
method
prefer
na
activ
low
discord
pair
use
two
assay
use
two
system
influenza
influenza
b
virus
tend
slightli
sensit
zanamivir
influenza
subtyp
tend
slightli
sensit
oseltamivir
drug
suscept
known
zanamivir
oseltamivirresist
mutant
fell
outsid
confid
limit
natur
isol
easili
distinguish
na
approxim
isol
control
virus
clinic
isol
includ
lie
confid
limit
sequenc
sequenc
reveal
variat
previous
conserv
residu
one
influenza
b
isol
n
g
e
v
origin
thought
proton
donor
catalyt
reaction
mediat
na
sinc
none
isol
show
decreas
enzym
activ
like
provid
role
addit
chang
nonconserv
residu
associ
natur
antigen
drift
also
chang
conserv
residu
b
viru
coevolut
b
isol
molecular
model
show
latter
two
residu
lie
opposit
side
na
head
henc
like
random
rather
compensatori
mutat
importantli
despit
sequenc
variat
natur
occur
resist
either
zanamivir
oseltamivir
effect
mutat
hemagglutinin
gene
influenza
virus
resist
phenotyp
neuraminidas
inhibitor
guy
boivin
laval
univers
canada
previou
studi
shown
resist
neuraminidas
inhibitor
nai
gener
vitro
passag
may
result
mutat
neuraminidas
na
andor
hemagglutinin
ha
gene
howev
effect
ha
mutat
alon
resist
phenotyp
remain
confirm
clinic
isol
influenza
ha
mutat
result
reduc
suscept
zanamivir
result
resist
known
nai
blick
et
al
mutat
incorpor
ha
transcript
plasmid
use
quick
chang
sitedirect
mutagenesi
kit
stratagen
recombin
influenza
virus
gener
revers
genet
fodor
et
al
na
inhibit
assay
wild
type
ha
mutant
similar
low
ic
valu
zanamivir
nm
peramivir
nm
viru
threeto
fourfold
reduct
suscept
plaqu
reduct
assay
two
mutant
differ
wild
type
viru
data
suggest
vitro
gener
resist
nai
may
sole
attribut
ha
mutat
previous
report
addit
combin
effect
ha
na
mutat
need
investig
potenti
mechan
nai
resist
nedyalkova
et
al
studi
also
document
util
revers
genet
studi
variou
ha
substitut
genet
background
impact
variant
antivir
suscept
two
specif
inhibitor
influenza
b
neuraminidas
current
avail
clinic
use
inhal
zanamivir
oral
oseltamivir
two
addit
oral
activ
neuraminidas
inhibitor
nai
peramivir
investig
although
current
plan
move
agent
forward
clinic
use
vitro
resist
mediat
chang
hemagglutinin
ha
strainspecif
chang
neuraminidas
na
subtypeand
drugspecif
creation
defect
na
reliabl
cell
culturebas
assay
current
wide
avail
influenza
viru
suscept
test
nai
drugselect
chang
na
detect
enzym
inhibit
assay
result
assay
affect
reaction
condit
vari
even
slightli
mixtur
variant
present
na
low
activ
resist
may
defin
greater
increas
ic
valu
compar
viru
recov
prior
drug
exposur
sequenc
na
ha
gene
done
document
genet
chang
may
associ
phenotyp
resist
resist
variant
also
recov
vivo
immunocompet
immunocompromis
patient
zanamivirselect
substitut
either
ha
na
recogn
immunocompet
person
oseltamivirselect
substitut
ha
recogn
howev
sever
oseltamivirselect
chang
na
influenza
virus
detect
found
treat
adult
children
develop
variant
therapi
clinic
cours
patient
detect
resist
variant
differ
suscept
virus
covington
et
al
gubareva
et
al
herloch
et
al
whitley
et
al
immunocompromis
patient
prolong
viru
shed
promot
emerg
drug
resist
studi
four
clinic
case
immunocompromis
patient
develop
nai
resist
mutant
recogn
first
patient
describ
elsewher
gubareva
et
al
girl
chronic
myelocyt
leukemia
underw
bone
marrow
transplant
develop
influenza
b
viru
infect
persist
death
despit
inhal
zanamivir
zanamivir
treatment
na
mutat
confer
crossresist
known
nai
ic
nm
zanamivir
nm
oseltamivir
peramivir
develop
addit
ha
mutat
note
well
second
patient
girl
chronic
myelocyt
leukemia
underw
bone
marrow
transplant
also
develop
influenza
b
infect
continu
death
patient
treat
oseltamivir
briefli
ribavirin
initi
isol
therapi
na
mutat
time
addit
na
mutat
develop
induc
decreas
suscept
oseltamivir
zanamivir
peramivir
ic
nm
respect
third
patient
male
underw
bone
marrow
transplant
acut
lymphocyt
leukemia
develop
influenza
infect
receiv
intermitt
therapi
amantadin
rimantadin
oseltamivir
zanamivir
die
month
later
detect
viru
initi
viru
avail
resist
assess
collect
sever
month
therapi
resist
inhibitor
mutat
mutat
na
confer
decreas
suscept
oseltamivir
ic
nm
peramivir
ic
nm
chang
zanamivir
suscept
ic
nm
respect
transient
detect
fourth
patient
femal
chronic
lymphocyt
leukemia
develop
influenza
infect
time
na
mutat
occur
confer
resist
oseltamivir
mutat
confer
inhibitor
resist
viru
resist
inhibitor
oseltamivir
emerg
patient
clear
antivir
therapi
fail
control
influenza
infect
novel
na
mutat
recogn
unlik
rapid
emerg
resist
inhibitor
select
influenza
virus
alter
na
usual
requir
prolong
drug
exposur
base
enzym
inhibit
assay
na
mutat
frequent
confer
resist
singl
nai
mechan
resist
nai
complex
requir
investig
futur
studi
assess
impact
ha
mutat
sialyat
ha
viru
depend
na
activ
nai
suscept
interest
respiratori
virus
greatli
expand
half
year
sinc
fifth
intern
symposium
respiratori
viral
infect
larg
result
emerg
sever
acut
respiratori
syndrom
sar
due
novel
coronaviru
although
sar
recogn
time
meet
symposium
succeed
review
recent
advanc
respiratori
viru
research
recent
event
associ
sar
epidem
outbreak
influenza
europ
emphas
import
plan
ahead
pandem
potenti
biolog
catastroph
meet
focus
import
pandem
plan
influenza
outlin
area
vaccin
develop
implement
need
continu
studi
develop
liveattenu
recombin
vaccin
hold
great
promis
prevent
viral
respiratori
diseas
futur
clearli
signific
challeng
lie
ahead
develop
antivir
activ
respiratori
virus
addit
common
respiratori
viral
pathogen
like
rhinovirus
rsv
threat
sar
novel
influenza
virus
highlight
medic
need
antivir
prevent
treatment
